Focused libraries of genetic packages

Abstract

Focused libraries of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of antibody peptides, polypeptides or proteins and collectively display, display and express, or comprise at least a portion of the focused diversity of the family. The libraries have length and sequence diversities that mimic that found in native human antibodies.

Description

[0001] This application claims the benefit under 35 USC .sctn. 120 of U.S. provisional application 60/256,380, filed Dec. 18, 2001. The provisional application and the Tables attached to it are specifically incorporated by reference herein.

[0002] The present invention relates to focused libraries of genetic packages that each display, display and express, or comprise a member of a diverse family of peptides, polypeptides or proteins and collectively display, display and express, or comprise at least a portion of the focused diversity of the family. The focused diversity of the libraries of this invention comprises both sequence diversity and length diversity. In a preferred embodiment, the focused diversity of the libraries of this invention is biased toward the natural diversity of the selected family. In a more preferred embodiment, the libraries are biased toward the natural diversity of human antibodies and are characterized by variegation in their heavy chain and light chain complementarity determining regions ("CDRs").

[0003] The present invention further relates to vectors and genetic packages (e.g., cells, spores or viruses) for displaying, or displaying and expressing a focused diverse family of peptides, polypeptides or proteins. In a preferred embodiment the genetic packages are filamentous phage or phagemids or yeast. Again, the focused diversity of the family comprises diversity in sequence and diversity in length.

[0004] The present invention further relates to methods of screening the focused libraries of the invention and to the peptides, polypeptides and proteins identified by such screening.

BACKGROUND OF THE INVENTION

[0005] It is now common practice in the art to prepare libraries of genetic packages that individually display, display and express, or comprise a member of a diverse family of peptides, polypeptides or proteins and collectively display, display and express, or comprise at least a portion of the amino acid diversity of the family. In many common libraries, the peptides, polypeptides or proteins are related to antibodies (e.g., single chain Fv (scFv), Fv, Fab, whole antibodies or minibodies (i.e., dimers that consist of V.sub.H linked to V.sub.L)). Often, they comprise one or more of the CDRs and framework regions of the heavy and light chains of human antibodies.

[0006] Peptide, polypeptide or protein libraries have been produced in several ways in the prior art. See e.g., Knappik et al., J. Mol. Biol., 296, pp. 57-86 (2000), which is incorporated herein by references. One method is to capture the diversity of native donors, either naive or immunized. Another way is to generate libraries having synthetic diversity. A third method is a combination of the first two. Typically, the diversity produced by these methods is limited to sequence diversity, i.e., each member of the library differs from the other members of the family by having different amino acids or variegation at a given position in the peptide, polypeptide or protein chain. Naturally diverse peptides, polypeptides or proteins, however, are not limited to diversity only in their amino acid sequences. For example, human antibodies are not limited to sequence diversity in their amino acids, they are also diverse in the lengths of their amino acid chains.

[0007] For antibodies, diversity in length occurs, for example, during variable region rearrangements. See e.g., Corbett et al., J. Mol. Biol., 270, pp. 587-97 (1997). The joining of V genes to J genes, for example, results in the inclusion of a recognizable D segment in CDR3 in about half of the heavy chain antibody sequences, thus creating regions encoding varying lengths of amino acids. The following also may occur during joining of antibody gene segments: (i) the end of the V gene may have zero to several bases deleted or changed; (ii) the end of the D segment may have zero to many bases removed or changed; (iii) a number of random bases may be inserted between V and D or between D and J; and (iv) the 5' end of J may be edited to remove or to change several bases. These rearrangements result in antibodies that are diverse both in amino acid sequence and in length.

[0008] Libraries that contain only amino acid sequence diversity are, thus, disadvantaged in that they do not reflect the natural diversity of the peptide, polypeptide or protein that the library is intended to mimic. Further, diversity in length may be important to the ultimate functioning of the protein, peptide or polypeptide. For example, with regard to a library comprising antibody regions, many of the peptides, polypeptides, proteins displayed, displayed and expressed, or comprised by the genetic packages of the library may not fold properly or their binding to an antigen may be disadvantaged, if diversity both in sequence and length are not represented in the library.

[0009] An additional disadvantage of prior art libraries of genetic packages that display, display and express, or comprise peptides, polypeptides and proteins is that they are not focused oh those members that are based on natural occurring diversity and thus on members that are most likely to be functional. Rather, the prior art libraries, typically, attempt to include as much diversity or variegation at every amino acid residue as possible. This makes library construction time-consuming and less efficient than possible. The large number of members that are produced by trying to capture complete diversity also makes screening more cumbersome than it needs to be. This is particularly true given that many members of the library will not be functional.

SUMMARY OF THE INVENTION

[0010] One objective of this invention is focused libraries of vectors or genetic packages that encode members of a diverse family of peptides, polypeptides or proteins wherein the libraries encode populations that are diverse in both length and sequence. The diverse length comprising components that contain motifs that are likely to fold and function in the context of the parental peptide, polypeptide or protein.

[0011] Another object of this invention is focused libraries of genetic packages that display, display and express, or comprise a member of a diverse family of peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the focused diversity of the family. These libraries are diverse not only in their amino acid sequences, but also in their lengths. And, their diversity is focused so as to more closely mimic or take into account the naturally-occurring diversity of the specific family that the library represents.

[0012] Another object of this invention is diverse, but focused, populations of DNA sequences encoding peptides, polypeptides or proteins suitable for display or display and expression using genetic packages (such as phage or phagemids) or other regimens that allow selection of specific binding components of a library.

[0013] A further object of this invention is focused libraries comprising the CDRs of human antibodies that are diverse in both their amino acid sequence and in their length (examples of such libraries include libraries of single chain Fv (scFv), Fv, Fab, whole antibodies or minibodies (i.e., dimers that consist of V.sub.H linked to V.sub.L)). Such regions may be from the heavy or light chains or both and may include one or more of the CDRs of those chains. More preferably, the diversity or variegation occurs in all of the heavy chain and light chain CDRs.

[0014] It is another object of this invention to provide methods of making and screening the above libraries and the peptides, polypeptides and proteins obtained in such screening.

[0015] Among the preferred embodiments of this invention are the following:

[0016] 1. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a heavy chain CDR1 selected from the group consisting of: [0017] (1) <1>.sub.1Y.sub.2<1>.sub.3M.sub.4<1>.sub.5, wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; [0018] (2) (S/T).sub.1(S/G/X).sub.2(S/G/X).sub.3Y.sub.4Y.sub.5W.sub.6(S/G/X).sub.7, wherein (S/T) is a 1:1 mixture of S and T residues, (S/G/X) is a mixture of 0.2025 S, 0.2025 G and 0.035 of each of amino acid residues A, D, E, F, H, I, K, L, M, N, P, Q, R, T, V, W, and Y; [0019] (3) V.sub.1S.sub.2G.sub.3G.sub.4S.sub.5I.sub.6S.sub.7<1>.sub.8<1>- .sub.9<1>.sub.10Y.sub.11Y.sub.12W.sub.13<1>.sub.14, wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; and [0020] (4) mixtures of vectors or genetic packages characterized by any of the above DNA sequences, preferably in the ratio: HC CDR1s (1):(2):(3)::0.80:0.17:0.02.

[0021] 2. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody facility, the vectors or genetic packages being characterized by variegated DNA sequences that encode a heavy chain CDR2 selected from the group consisting of: [0022] (1) <2>I<2><3>SGG<1>T<1>YADSVKG, wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; <2> is an equimolar mixture of each of amino acid residues Y, R, W, V, G, and S; and <3> is an equimolar mixture of each of amino acid residues P, S, and G or an equimolar mixture of P and S; [0023] (2) <1>I<4><1><1><G><5><1><1>- <1>YADSVKG, herein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; <4> is an equimolar mixture of residues D, I, N, S, W, Y; and <5> is an equimolar mixture of residues S, G, D and N; [0024] (3) <1>I<4><1><1>G<5><1><1>YNPS- LKG, wnerein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and <4> and <5> are as defined above; [0025] (4) <1>I<8>S<1><1><1>GGYY<1>YAASVKG, wherein <1> is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; <8> is 0.27 R and 0.027 of each of ADEFGHIKLMNPQSTVWY; and [0026] (5) mixtures of vectors or genetic packages characterized by any of the above DNA sequences, preferably in the ratio: HC CDR2s: (1)/(2) (equimolar): (3):(4)::0.54:0.43:0.03.

[0027] 3. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a heavy chain CDR3 selected from the group consisting of: [0028] (1) YYCA21111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R; [0029] (2) YYCA2111111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R; [0030] (3) YYCA211111111YFDAYTG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R; [0031] (4) YYCAR111S2S3111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of S and G; and 3 is an equimolar mixture of Y and W; [0032] (5) YYCA2111CSG11CY1YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R; [0033] (6) YYCA211S1TIFG11111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R; [0034] (7) YYCAR111YY2S3344111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; 2 is an equimolar mixture of D and S; and 3 is an equimolar mixture of S and G; [0035] (8) YYCAR1111YC2231CY111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; 2 is an equimolar mixture of S and G; and 3 is an equimolar mixture of T, D and G; and [0036] (9) mixtures of vectors or genetic packages characterized by any of the above DNA sequences, preferably the HC CDR3s (1) through (8) are in the following proportions in the mixture: [0037] (1) 0.10 [0038] (2) 0.14 [0039] (3) 0.25 [0040] (4) 0.13 [0041] (5) 0.13 [0042] (6) 0.11

[0043] (7) 0.04 and [0044] (8) 0.10; and more preferably the HC CDR3s (1) through (8) are in the following proportions in the mixture: [0045] (1) 0.02 [0046] (2) 0.14 [0047] (3) 0.25 [0048] (4) 0.14 [0049] (5) 0.14 [0050] (6) 0.12 [0051] (7) 0.08 and [0052] (8) 0.11.

[0053] Preferably, 1 in one or all of HC CDR3s (1) through (8) is 0.095 of each of G and Y and 0.048 of each of A, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, and W.

[0054] 4. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encodes a kappa light chain CDR1 selected from the group consisting of: [0055] (1) RASQ<1>V<2><2><3>LA [0056] (2) RASQ<1>V<2><2><2><3>LA; wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <2> is 0.2 S and 0.044 of each of ADEFGHIKLMNPQRTVWY; and <3> is 0.2Y and 0.044 each of ADEFGHIKLMNPQRTVW and Y; and [0057] (3) mixtures of vectors or genetic packages characterized by any of the above DNA sequences, preferably in the ratio CDR1s (1):(2)::0.68:0.32.

[0058] 5. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a kappa light chain CDR2 having the sequence: [0059] <1>AS<2>R<4><1>, wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <2> is 0.2 S and 0.044 of each of ADEFGHIKLMNPQRTVWY; and <4> is 0.2 A and) 0.044 each of DEFGHIKLMNPQRSTVWY.

[0060] 6. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a kappa light chain CDR3 selected from the groups consisting of: [0061] (1) QQ<3><1><1><1>P<1>T, wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <3> is 0.2 Y and 0.044 each of ADEFGHIKLMNPQRTVW; [0062] (2) QQ33111P, wherein 1 and 3 are as defined in (1) above; [0063] (3) QQ3211PP1T, wherein 1 and 3 are as defined in (1) above and 2 is 0.2 S and 0.044 each of ADEFGHIKLMNPQRTVWY; and [0064] (4) mixtures of vectors or genetic packages characterized by any of the above DNA sequences, preferably in the ratio CDR3s (1):(2):(3)::0.65:0.1:0.25.

[0065] 7. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a lambda light chain CDR1 selected from the group consisting of: [0066] (1) TG<1>SS<2>VG<1><3><2><3>VS, wherein <1> is 0.27 T, 0.27 G and 0.027 each of ADEFHIKLMNPQRSVWY, <2> is 0.27 D, 0.27 N and 0.027 each of AEFGHIKLMPQRSTVWY, and <3> is 0.36 Y and 0.036 each of ADEFGHIKLMNPQRSTVW; [0067] (2) G<2><4>L<4><4><4><3><4><4&gt- ;, wherein <2> is as defined in (1) above and <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; and [0068] (3) mixtures of vectors or genetic packages characterized by any of the above DNA sequences, preferably in the ratio CDR1s (1):(2)::0.67:0.33.

[0069] 8. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a lambda light chain CDR2 has the sequence: [0070] <4><4><4><2>RPS, wherein <2> is 0.27 D, 0.27 N, and 0.027 each of AEFGHIKLMPQRSTVWY and <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVW.

[0071] 9. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a lambda light chain CDR3 selected from the group consisting of: [0072] (1) <4><5><4><2><4>S<4><4><4>- <4>V, wherein <2> is 0.27 D, 0.27 N, and 0.027 each of AEFGHIKLMPQRSTVWY; <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVW; and <5> is 0.36 S and 0.0355 each of ADEFGHIKLMNPQRTVWY; [0073] (2) <5>SY<1><5>S<5><1><4>V, wherein <1> is an equimolar mixture of ADEFGHIKLMNPQRSTVWY; and <4> and <5> are as defined in (1) above; and [0074] (3) mixtures of vectors or genetic packages characterized by any of the above DNA sequences, preferably in the ratio CDR3s (1):(2)::1:1.

[0075] 10. A focused library comprising variegated DNA sequences that encode a heavy chain CDR selected from the group consisting of: [0076] (1) one or more of the heavy chain CDR1s of paragraph 1 above; [0077] (2) one or more of the heavy chain CDR2s of paragraph 2 above; [0078] (3) one or more of the heavy chain CDR3s of paragraph 3 above; and [0079] (4) mixtures of vectors or genetic packages characterized by (1), (2) and (3).

[0080] 11. The focused library comprising one or more of the variegated DNA sequences that encodes a heavy chain CDR of paragraphs 1, 2 and 3 and further comprising variegated DNA sequences that encodes a light chain CDR selected from the group consisting of [0081] (1) one or more the kappa light chain CDR1s of paragraph 4; [0082] (2) the kappa light chain CDR2 of paragraph 5; [0083] (3) one or more of the kappa light chain CDR3s of paragraph 6; [0084] (4) one or more of the kappa light chain CDR1s of paragraph 7; [0085] (5) the lambda light chain CDR2 of paragraph 8; [0086] (6) one or more of the lambda light chain CDR3s of paragraph 9; and [0087] (7) mixtures of vectors and genetic packages characterized by one or more of (1) through (6).

[0088] 12. A population of variegated DNA sequences as described in paragraphs 1-11 above.

[0089] 13. A population of vectors comprising the variegated DNA sequences as described in paragraphs 1-11 above.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0090] Antibodies ("Ab") concentrate their diversity into those regions that are involved in determining affinity and specificity of the Ab for particular targets. These regions may be diverse in sequence or in length. Generally, they are diverse in both ways. However, within families of human antibodies the diversities, both in sequence and in length, are not truly random. Rather, some amino acid residues are preferred at certain positions of the CDRs and some CDR lengths are preferred. These preferred diversities account for the natural diversity of the antibody family.

[0091] According to this invention, and as more fully described below, libraries of vectors and genetic packages that more closely mirror the natural diversity, both in sequence and in length, of antibody families, or portions thereof are prepared and used.

Human Antibody Heavy Chain Sequence and Length Diversity

[0092] (a) Framework

[0093] The heavy chain ("HC") Germ-Line Gene (GLG) 3-23 (also known as VP-47) accounts for about 12% of all human Abs and is preferred as the framework in the preferred embodiment of the invention. It should, however, be understood that other well-known frameworks, such as 4-34, 3-30, 3-30.3 and 4-30.1, may also be used without departing from the principles of the focused diversities of this invention.

[0094] In addition, JH4 (YFDYWGQGTLVTUSS) occurs more often than JH3 in native antibodies. Hence, it is preferred for the focused libraries of this invention. However, JH3 (AFDIWGQGTMVTVSS) could as well be used.

[0095] (b) Focused Length Diversity: CDR1, 2 and 3

[0096] (i) CDR1

[0097] For CDR1, GLGs provide CDR1s only of the lengths 5, 6, and 7. Mutations during the maturation of the V-domain gene, however, can lead to CDR1s having lengths as short as 2 and as long as 16. Nevertheless, length 5 predominates. Accordingly, in the preferred embodiment of this invention, the preferred HC CDR1 is 5 amino acids, with less preferred CDR is having lengths of 7 and 14. In the most preferred libraries of this invention, all three lengths are used in proportions similar to those found in natural antibodies.

[0098] (ii) CDR2

[0099] GLGs provide CDR2s only of the lengths 15-19, but mutations during maturation may result in CDR2s of lengths from 16 to 28 amino acids. The lengths 16 and 17 predominate in mature Ab genes. Accordingly, length 17 is the preferred length for HC CDR2 of the present invention. Less preferred HC CDR2s of this invention have lengths 16 and 19. In the most preferred focused libraries of this invention, all three lengths are included in proportions similar to those found in natural antibody families.

[0100] (iii) CDR3

[0101] HC CDR3s vary in length. About half of human HCs consist of the components: V::nz::D::ny::JHn where V is a V gene, nz is a series of bases (mean 12) that are essentially random, D is a D segment, often with heavy editing at both ends, ny is a series of bases (mean 6) that are essentially random, and JH is one of the six JH segments, often with heavy editing at the 5' end. The D segments appear to provide spacer segments that allow folding of the IgG. The greatest diversity is at the junctions of V with D and of D with JH.

[0102] In the preferred libraries of this invention both types of HC CDR3s are used. In HC CDR3s that have no identifiable D segment, the structure is V::nz::JHn where JH is usually edited at the 51 end. In HC CDR3s that have an identifiable D segment, the structure is V::nz::D::ny::JHn.

[0103] (c) Focused Sequence Diversity: CDR1, 2 and 3

[0104] (i) CDR1

[0105] In 5 amino acid length CDR1, examination of a 3D model of a humanized Ab showed that the side groups of residues 1, 3, and 5 were directed toward the combining pocket. Consequently, in the focused libraries of this invention, each of these positions may be selected from any of the native amino acid residues, except cysteine ("C"). Cysteine can form disulfide bonds, which are an important component of the canonical Ig fold. Having free thiol groups could, thus, interfere with proper folding of the HC and could lead to problems in production or manipulation of selected Abs. Thus, in the focused libraries of this invention cysteine is excluded from positions 1, 3 and 5 of the preferred 5 amino acid CDR1s. The other 19 natural amino acids residues may be used at positions 1, 3 and 5. Preferably, each is present in equimolar ratios in the variegated libraries of this invention.

[0106] 3D modeling also suggests that the side groups of residue 2 in a 5 amino acid CDR1 are directed away from the combining-pocket. Although this position shows substantial diversity, both in GLG and mature genes, in the focused libraries of this invention this residue is preferably Tyr (Y) because it occurs in 681/820 mature antibody genes. However, any of the other native amino acid residues, except Cys (C), could also be used at this position.

[0107] For position 4, there is also some diversity in GLG and mature antibody genes. However, almost all mature genes have uncharged hydrophobic amino acid residues: A, G, L, P, F, M, W, I, V, at this position. Inspection of a 3D model also shows that the side group of residue 4 is packed into the innards of the HC. Thus, in the preferred embodiment of this invention which uses framework 3-23, residue 4 is preferably Met because it is likely to fit very well into the framework of 3-23. With other frameworks, a similar fit consideration is used to assign residue 4.

[0108] Thus, the most preferred HC CDR1 of this invention consists of the amino acid sequence <1>Y<1>M<1>where <1> can be any one of amino acid residues: A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T,. V, W, Y (not C), preferably present at each position in an equimolar amount. This diversity is shown in the context of a framework 3-23:JH4 in Table 1. It has a diversity of 6859-fold.

[0109] The two less preferred HC CDR1s of this invention have length 7 and length 14. For length 7, a preferred variegation is (S/T).sub.1(S/G/<1>).sub.2(S/G/<1>).sub.3Y.sub.4Y.sub.5W.sub.- 6(S/G/<1>).sub.7; where (S/T) indicates an equimolar mixture of Ser and Thr codons; (S/G/<1>) indicates a mixture of 0.2025 S, 0.2025 G, and 0.035 for each of A, D, E, F, H, I, K, L, M, N, P, Q, R, T, V, W, Y. This design gives a predominance of Ser and Gly at positions 2, 3, and 7, as occurs in mature HC genes. For length 14, a preferred variegation is VSGGSIS<1><1><1>YYW<1>, where <1> is an equimolar mixture of the 19 native amino acid residues, except Cys (C).

[0110] The DNA that encodes these preferred HC CDR1s is preferably synthesized using trinucleotide building blocks so that each amino acid residue is present in essentially equimolar or other described amounts. The preferred codons for the <1> amino acid residues are gct, gat, gag, ttt, ggt, cat, att, aag, ctt, atg, aat, cct, cag, cgt, tct, act, gtt, tgg, and tat. Of course, other codons for the chosen amino acid residue could also be used.

[0111] The diversity oligonucleotide (ON) is preferably synthesized from BspEI to BstXI (as shown in Table 1) and can, therefore, be incorporated either by PCR synthesis using overlapping ONs or introduced by ligation of BspEI/BstXI-cut fragments. Table 2 shows the oligonucleotides that embody the specified variegations of the preferred length 5 HC CDR1s of this invention. PCR using ON-R1V1vg, ON-R1top, and ON-R1bot gives a dsDNA product of 73 base pairs, cleavage with BspEI and BstXI trims 11 and 13 bases from the ends and provides cohesive ends that can be ligated to similarly cut vector having the 3-23 domain shown in Table 1. Replacement of ON-R1V1vg with either ONR1V2vg or ONR1V3vg (see Table 2) allows synthesis of the two alternative diversity patterns--the 7 residue length and the 14 residue length HC CDR1.

[0112] The more preferred libraries of this invention comprise the 3 preferred HC CDR1 length diversities. Most preferably, the 3 lengths should be incorporated in approximately the ratios in which they are observed in antibodies selected without reference to the length of the CDRs. For example, one sample of 1095 HC genes have the three lengths present in the ratio: L=5:L=7:L=14::820:175:23::0.80:0.17:0.02. This is the preferred ratio in accordance with this invention.

[0113] (ii) CDR2

[0114] Diversity in HC CDR2 was designed with the same considerations as for HC CDR1: GLG sequences, mature sequences and 3D structure. A preferred length for CDR2 is 17, as shown in Table 1. For this preferred 17 length CDR2, the preferred variegation in accordance with the invention is: <2>I<2><3>SGG<1>T<1>YADSVKG, where <2>indicates any amino acid residue selected from the group of Y, R, W, V, G and S (equimolar mixture), <3> is P, S and G or P and S only (equimolar mixture), and <1> is any native amino acid residue except C (equimolar mixture).

[0115] ON-R2V1vg shown in Table 3 embodies this diversity pattern. It is preferably synthesized so that fragments of dsDNA containing the BstXI and XbaI site can be generated by PCR. PCR with ON-R2V1vg, ON-R2top, and ONR2bot gives a dsDNA product of 122 base pairs. Cleavage with BstXI and XbaI removes about 10 bases from each end and produces cohesive ends that can be ligated to similarly cut vector that contains the 3-23gene shown in Table 1.

[0116] In an alternative embodiment for a 17 length HC CDR2, the following variegation may be used: <1>I<4><1><1>G<5><1><1><1&gt- ;YADSVKG, where <1> is as described above for the more preferred alternative of HC CDR2; <4> indicates an equimolar mixture of DINSWY, and <5> indicates an equimolar mixture of SGDN. This diversity pattern is embodied in ON-R2V2vg shown in Table 3. Preferably, the two embodiments are used in equimolar mixtures in the libraries of this invention.

[0117] Other preferred HC CDR2s have lengths 16 and 19. Length 16: <1>I<4><1><1>G<5<1><1>YNPSLKG; Length 19: <1>I<8>S<1><1><1>GGYY<1>YAASVKG, wherein <1> is an equimolar mixture of all native amino acid residues except C; <4> is a equimolar mixture of DINSWY; <5> is an equimolar mixture of SGDN; and <8> is 0.27 R and 0.027 of each of residues ADEFGHIKLMNPQSTVWY. Table 3 shows ON-R2V3vg which embodies a preferred CDR2 variegation of length 16 and ON-R2V4vg which embodies a preferred CDR2 variegation of length 19. To prepare these variegations ON-R2V3vg may be PCR amplified with ON-R2top and ON-R2bo3 and ON-R2V4vg may be PCR amplified with ON-R2top and ON-R2-bo4. See Table 3. In the most preferred embodiment of this invention, all three HC CDR2 lengths are used. Preferably, they are present in a ratio 17:16:19::579:464:31::0.54:0.43:0.03.

[0118] (iii) CDR3

[0119] The preferred libraries of this invention comprise several HC CDR3 components. Some of these will have only sequence diversity. Others will have sequence diversity with embedded D segments to extend the length, while also incorporating sequences known to allow Igs to fold. The HC CDR3 components of the preferred libraries of this invention and their diversities are depicted in Table 4: Components 1-8.

[0120] This set of components was chosen after studying the sequences of 1383 human HC sequences. The proposed components are meant to fulfill the following goals:

[0121] 1) approximately the same distribution of lengths as seen in native Ab genes;

[0122] 2) high level of sequence diversity at places having high diversity in native Ab genes; and

[0123] 3) incorporation of constant sequences often seen in native Ab genes.

[0124] Component 1 represents all the genes having lengths 0 to 8 (counting from the YYCAR motif at the end of FR3 to the WG dipeptide motif near the start of the J region, i.e., FR4). Component 2 corresponds the all the genes having lengths 9 or 10. Component 3 corresponds to the genes having lengths 11 or 12 plus half the genes having length 13. Component 4 corresponds to those having length 14 plus half those having length 13. Component 5 corresponds to the genes having length 15 and half of those having length 16. Component 6 corresponds to genes of length 17 plus half of those with length 16. Component 7 corresponds to those with length 18. Component 8 corresponds to those having length 19 and greater. See Table 4.

[0125] For each HC CDR3 residue having the diversity <1>, equimolar ratios are preferably not used. Rather, the following ratios are used 0.095 [G and Y] and 0.048 [A, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, and W]. Thus, there is a double dose of G and Y with the other residues being in equimolar ratios. For the other diversities, e.g., KR or SG, the residues are present in equimolar mixtures.

[0126] In the preferred libraries of this invention the eight components are present in the following fractions: 1 (0.10), 2 (0.14), 3 (0.25), 4 (0.13), 5 (0.13), 6 (0.11), 7 (0.04) and 8 (0.10). See Table 4.

[0127] In the more preferred embodiment of this invention, the amounts of the eight components is adjusted because the first component is not complex enough to justify including it as 10% of the library. For example, if the final library were to have 1.times.10.sup.9 members, then 1.times.10.sup.8 sequences would come from component 1, but it has only 2.6.times.10.sup.5 CDR3 sequences so that each one would occur in .about.385 CDR1/2 contexts. Therefore, the more preferred amounts of the eight components are 1(0.02), 2(0.14), 3(0.25), 4(0.14), 5(0.14), 6(0.12), 7(0.08), 8(0.11). In accordance with the more preferred embodiment component 1 occurs in .about.77 CDR1/2 contexts and the other, longer CDR3s occur more often.

[0128] Table 5 shows vgDNA that embodies each of the eight HC CDR3 components shown in Table 4. In Table 5, the oligonucleotides (ON) Ctop25, CtprmA, CBprmB, and CBot25 allow PCR amplification of each of the variegated ONs (vgDNA): C1t08, C2t10, C3t12, C4t14, C5t15, C6t17, C7t18, and C8t19. After amplification, the dsDNA can be cleaved with AflII and BstEII (or KpnI) and ligated to similarly cleaved vector that contains the remainder of the 3-23 domain. Preferably, this vector already contains diversity in one, or both, of CDR1 and CDR2 as disclosed herein. Most preferably, it contains diversity in both the CDR1 and CDR2 regions. It is, of course, to be understood that the various diversities can be incorporated into the vector in any order.

[0129] Preferably, the recipient vector originally contains a stuffer in place of CDR1, CDR2 and CDR3 so that there will be no parental sequence that would then occur in the resulting library. Table 6 shows a version of the V3-23 gene segment with each CDR replaced by a short segment that contains both stop codons and restriction sites that will allow specific cleavage of any vector that does not have the stuffer removed. The stuffer can either be short and contain a restriction enzyme site that will not occur in the finished library, allowing removal of vectors that are not cleaved by both AflII and BstEII (or KpnI) and religated. Alternatively, the stuffer could be 200-400 bases long so that uncleaved or once cleaved vector can be readily separated from doubly cleaved vector.

Human Antibody Light Chain: Sequence and Length Diversity

[0130] (i) Kappa Chain

[0131] (a) Framework

[0132] In the preferred embodiment of this invention, the kappa light chain is built in an A27 framework with a JK1 region. These are the most common V and J regions in the native genes. Other frameworks, such as 012, L2, and A11, and other J regions, such as JK4, however, may be used without departing from the scope of this invention.

[0133] (b) CDR1

[0134] In native human kappa chains, CDR1s with lengths of 11, 12, 13, 16, and 17 were observed with length 11 being predominant and length 12 being well represented. Thus, in the preferred embodiments of this invention LC CDR1s of length 11 and 12 are used in an and mixture similar to that observed in native antibodies), length 11 being most preferred. Length 11 has the following sequence: RASQ<1>V<2><2><3>LA and Length 12 has the following sequence: RASQ<1>V<2><2><2><3>LA, wherein <1> is an equimolar mixture of all of the native amino acid residues, except C, <2> is 0.2 S and 0.044 of each of ADEFGHIKLMNPQRTVWY, and <3> is 0.2 Y and 0.044 each of A, D, E, F, G, H, I, K, L, M, N, P, Q, R, T, V, W and Y. In the most preferred embodiment of this invention, both CDR1 lengths are used. Preferably, they are present in a ratio of 11:12::154:73::0.68:0.32.

[0135] (c) CDR2

[0136] In native kappa, CDR2 exhibits only length 7. This length is used in the preferred embodiments of this invention. It has the sequence <1>AS<2>R<4><1>, wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <2> is 0.2 S and 0.004 of each of ADEFGHIKLMNPQRTVWY; and <4> is 0.2 A and 0.044 of each of DEFGHIKLMNPQRSTUWY.

[0137] (d) CDR3

[0138] In native kappa, CDR3 exhibits lengths of 1, 4, 6, 7, 8, 9, 10, 11, 12, 13, and 19. While any of these lengths and mixtures of them can be employed in this invention, we prefer lengths 8, 9 and 10, length 9 being more preferred. For the preferred Length 9, the sequence is QQ<3><1><1><1>P<1>T, wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY and <3> is 0.2 Y and 0.044 each of ADEFGHIKLMNPQRSVW. Length 8 is preferably QQ33111P and Length 10 is preferably QQ3211PP1T, wherein 1 and 3 are as defined for Length 9 and 2 is S (0.2) and 0.044 each of ADEFGHIKLMNPQRTVWY. A mixture of all 3 lengths being most preferred (ratios as in native antibodies), i.e., 8:9:10::28:166:63::0.1:0.65:0.25.

[0139] Table 7 shows a kappa chain gene of this invention, including a PlacZ promoter, a ribosome-binding site, and signal sequence (M13 III signal). The DNA sequence encodes the GLG amino acid sequence, but does not comprise the GLG DNA sequence. Restriction sites are designed to fall within each framework region so that diversity can be cloned into the CDRs. XmaI and EspI are in FR1, SexAI is in FR2, RsrII is in FR3, and KpnI (or Acc65I) are in FR4. Additional sites are provided in the constant kappa chain to facilitate construction of the gene.

[0140] Table 7 also shows a suitable scheme of variegation for kappa. In CDR1, the most preferred length 11 is depicted. However, most preferably both lengths 11 and 12 are used. Length 12 in CDR1 can be construed by introducing codon 51 as <2> (i.e. a Ser-biased mixture). CDR2 of kappa is always 7 codons. Table 7 shows a preferred variegation scheme for CDR2. Table 7 shows a variegation scheme for the most preferred CDR3 (length 9). Similar variegations can be used for CDRs of length 8 and 10. In the preferred embodiment of this invention, those three lengths (8, 9 and 10) are included in the libraries of this invention in the native ratios, as described above.

[0141] Table 9 shows series of diversity oligonucleotides and primers that may be used to construct the kappa chain diversities depicted in Table 7.

[0142] (ii) Lambda Chain

[0143] (a) Framework

[0144] The lambda chain is preferably built in a 2a2 framework with an L2J region. These are the most common V and J regions in the native genes. Other frameworks, such as 31, 4b, 1a and 6a, and other J regions, such as L1J, L3J and L7J, however, may be used without departing from the scope of this invention.

[0145] (b) CDR1

[0146] In native human lambda chains, CDR1s with length 14 predominate, lengths 11, 12 and 13 also occur. While any of these can be used in this invention, lengths 11 and 14 are preferred. For length 11 the sequence is: TG<2><4>L<4><4><4><3><4>&lt- ;4>and for Length 14 the sequence is: TG<1>5S<2>VG<1><3><2><3>VS, wherein <1> is 0.27 T, 0.27 G and 0.027 each of ADEFHIKLMNPQRSVWY; <2> is 0.27 D, 0.27 N and 0.027 each of AEFGHIKLMPQRSTVWY; <3> is 0.36 Y and 0.0355 each of ADEFGHIKLMNPQRSTVW; and <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY. Most preferably, mixtures (similar to those occurring in native antibodies) preferably, the ratio is 11:14::23:46::0.33: 0.67 of the three lengths are used.

[0147] (c) CDR2

[0148] In native human lambda chains, CDR2s with length 7 are by far the most common. This length is preferred in this invention. The sequence of this Length 7 CDR2 is <4><4><4><2>RPS, wherein <2> is 0.27 D, 0.27 N, and 0.027 each of AEFGHIKLMPQRSTVWY and <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVW.

[0149] (d) CDR3

[0150] In native human lambda chains, CDR3s of length 10 and 11 predominate, while length 9 is also common. Any of these three lengths can be used in the invention. Length 11 is preferred and mixtures of 10 and 11 more preferred. The sequence of Length 11 is <4><5><4><2><4>S<4><4><4>- <4>V, where <2> and <4> are as defined for the lambda CDR1 and <5> is 0.36 S and 0.0355 each of ADFFGHIKLMNPQRTVWY. The sequence of Length 10 is <5>SY<1><5>S<5><1><4>V, wherein <1> is an equimolar mixture of ADEFGHIKLMNPQRSTVWY; and <4> and <5> are as defined for Length 11. The preferred mixtures of this invention comprise an equimolar mixture of Length 10 and Length 11. Table 8 shows a preferred focused lambda light chain diversity in accordance with this invention.

[0151] Table 9 shows a series of diversity oligonucleotides and primers that may be used to construct the lambda chain diversities depicted in Table 7.

Method of Construction of the Genetic Package

[0152] The diversities of heavy chain and the kappa and lambda light chains are best constructed in separate vectors. First a synthetic gene is designed to embody each of the synthetic variable domains. The light chains are bounded by restriction sites for ApaLI (positioned at the very end of the signal sequence) and AscI (positioned afer the stop codon). The heavy chain is bounded by SfiI (positioned within the Pe1B signal sequence) and NotI (positioned in the linker between CH1 and the anchor protein). Signal sequences other than Pe1B may also need, e.g., a M13 pIII signal sequence.

[0153] The initial genes are made with "stuffer" sequences in place of the desired CDRs. A "Stuffer" is a sequence that is to be cut away and replaced by diverse DNA but which does not allow expression of a functional antibody gene. For example, the stuffer may contain several stop codons and restriction sites that will not occur in the correct finished library vector. For example, in Table 10, the stuffer for CDR1 of kappa A27 contains a StuI site. The vgDNA for CDR1 is introduced as a cassette from EspI, XmaI, or AflII to either SexAI or KasI. After the ligation, the DNA is cleaved with StuI; there should be no StuI sites in the desired vectors.

[0154] The sequences of the heavy chain gene with stuffers is depicted in Table 6. The sequences of the kappa light chain gene with stuffers is depicted in Table 10. The sequence of the lambda light chain gene with stuffers is depicted in Table 11.

[0155] In another embodiment of the present intention the diversities of heavy chain and the kappa or lambda light chains are constructed in a single vector or genetic packages (e.g., for display or display and expression) having appropriate restriction sites that allow cloning of these chains. The processes to construct such vectors are well known and widely used in the art. Preferably, a heavy chain and Kappa light chain library and a heavy chain and lambda light chain library would be prepared separately. The two libraries, most preferably, will then be mixed in equimolar amounts to attain maximum diversity.

[0156] Most preferably, the display is had on the surface of a derivative of M13 phage. The most preferred vector contains all the genes of M13, an antibiotic resistance gene, and the display cassette. The preferred vector is provided with restriction sites that allow introduction and excision of members of the diverse family of genes, as cassettes. The preferred vector is stable against rearrangement under the growth conditions used to amplify phage.

[0157] In another embodiment of this invention, the diversity captured by the methods of the present invention may be displayed and/or expressed in a phagemid vector (e.g., pCES1) that displays and/or expresses the peptide, polypeptide or protein. Such vectors may also be used to store the diversity for subsequent display and/or expression using other vectors or phage.

[0158] In another embodiment of this invention, the diversity captured by the methods of the present invention may be displayed and/or expressed in a yeast vector. TABLE-US-00001 TABLE 1 3-23:JH4 CDR1/2 diversity = 1.78 .times. 10.sup.8 FR1 (VP47/V3-23)....... 20 21 22 23 24 25 26 27 28 29 30 A M A E V Q L L E S G ctgtctgaac cc atg gcc gaa|gtt|caa|ttg|tta|gag|tct|ggt| Scab...... NcoI.... MfeI -------------FR1--------------------------------- 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 G G L V Q P G G S L R L S C A |ggc|ggt|cct|gtt|cag|cct|ggt|ggt|tct|tta|cgt|ctt|tct|tgc|gtc| Sites of variegation <1> <1> <1> <1> 6859-fold diversity ----FR1------------------->|.....CDR1..................|---FR2------ 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 A S G F T F S - Y - M - W V R |gct|tcc|gga|ttc|act|ttc|tct|-|tac|-|atg|-|tgg|gtt|cgc| BspEI BsiWI BstXI. Sites of variegation-><2> <2> <3> -------FR2-------------------------------->|...CDR2.......... 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 Q A P G K G L E W V S - I - - |caa|gct|cct|ggt|aaa|ggt|ttg|gag|tgg|gtt|tct| - |atc| - | - | ...BstXI <1> <1> 25992-fold diversity in CDR2 ....CDR2............................................|---FR3--- 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 S G G - T - Y A D S V K G R F |tct|ggt|ggc| - |act| - |tat|gct|gac|tcc|gtt|aaa|ggt|cgc|ttc| -------FR3--------------------------------------------------- 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 T I S R D N S K N T L Y L Q M |act|atc|tct|aga|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg| XbaI ---FR3---------------------------------------------------->| 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 N S L R A E D T A V Y Y C A K |aac|agc|tta|agg|gct|gag|tac|acc|gct|gtc|tac|tac|tgc|gcc|aaa| AflII .......CDR3.................| Replaced by the various components! 121 122 123 124 125 126 127 D Y E G T G Y |gac|tat|gaa|ggt|act|ggt|tat| |------FRV----(JH4)------------------------------------------ Y F D Y W G Q G T L V T V S S |tat|ttc|gat|tat|tgg|ggt|caa|ggt|acc|ctg|gtc|acc|gtc|tct|agt|... KpnI BstEII <1> = Codons for ADEFGHIKLMNPQRSTVWY (equimolar mixture) <2> = Codons for YRWVGS (equimolar mixture) <3> = Codons for PS or PS and G (equimolar mixture)

[0159] TABLE-US-00002 TABLE 2 OligoNucleotides used to variegate CDR1 of human HC CDR1 - 5 residues (ON-R1V1vg): 5'ct|tcc|gga|ttc|act|ttc|tct|<1>|tac|<1>|atg|<1>|tgg|gt- t|cgc|caa|gct|cct|gg|-3' (ON-R1top): 5'-cctactgtct|tcc|gga|ttc|act|ttc|tct-3' (ON-R1bot) [RC]: 5'-tgg|gtt|cgc|caa|gct|cct|ggttgctcactc-3' CDR1 - 7 residues (ON-R1V2vg): 5'-ct|tcc|gga|ttc|act|ttc|tct|<6>|<7>|<7>|tac|tac|tgg|&- lt;7>|tgg|gtt|cgc|caa|gct| cct|gg-3' CDR1 - 14 residues (ON-R1V3vg): 5'-ct|tcc|gga|ttc|act|ttc|tct|atc|agc|ggt|ggt|tct|atc|tcc|<1>|<1- >|<1>|- tac|tac|tgg|<1>|tgg|gtt|cgc|caa|gct|cct|gg-3' <1> = Codons of ADEFGHIKLMNPQRSTVWY 1:1 <6> = Codons for ST, 1:1 <7> = 0.2025 (Codons for SG) + 0.035 (Codons for ADEFHIKLMNPQRTVWY) <1> = Codons for ADEFGHIKLMNPQRSTVWY 1:1

[0160] TABLE-US-00003 TABLE 3 Oligonucleotides used to variegate CDR2 of human HC CDR2 - 17 residues (ON-R2V1vg): 5'-ggt|ttg|gag|tgg|gtt|tct|<2>|atc|<2>|<3>|tct|ggt|ggc|- <1>|act|<1>|tat|gct|- gac|tcc|gtt|aaa|gg-3' (ON-R2top): 5'-ct|tgg|gtt|cgc|caa|gct|cct|ggt|aaa|ggt|ttg|gag|tgg|gtt|tct-3' (ON-R2bot) [RC]: 5'-tat|gct|gac|tcc|gtt|aaa|ggt|cgc|ttc|act|atc|tct|aga|ttcctgtcac-3' (ON-R2V2vg): 5'-ggt|ttg|gag|tgg|gtt|tct|<1>|atc|<4>|<1>|<1>|gg- t|<5>|<1>|<1>|<1>|tat|gct|- gac|tcc|gtt|aaa|gg-3' CDR2 - 16 residues (ON-R2V3vg): 5'-ggt|ttg|gag|tgg|gtt|tct|<1>|atc|<4>|<1>|<1>|gg- t| <5>|<1>|<1>|tat|aac|cct|tcc|ctt|aag|gg-3' (ON-R2bo3) [RC]: 5'-tat|aac|cct|tcc|ctt|aag|ggt|cgc|ttc|act|tct|aga|ttcctgtcac-3' CDR2 - 19 residues (ON-R2V4vg): 5'-fft|ttg|gag|tgg|gtt|tct|<1>|atc|<8|agt|<1>|<1>| <1>|ggt|ggt|act|act|<1>|tat|gcc|gct|tcc|gtt|aag|gg-3' (ON-R2bo4) [RC]: 5'-tat|gcc|gct|tcc|gtt|aag|ggt|cgc|ttc|act|atc|tct|aga|ttcctgtcac-3' <1> = Codons for A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y (equimolar mixture) <2> = Codons for Y, R, W, V, G and S (equimolar mixture) <3> = Codons for P and S (equimolar mixture) or P, S and G (equimolar mixture) <4> =Codons for DINSWY (equimolar mixture) <5> =Codons for SGDN, (equimolar mixture) <1>, <2>, <3>, <4> and <5> are as defined above <8> is 0.27 R and 0.027 each of ADEFGHIKLMNPQSTVWY

[0161] TABLE-US-00004 TABLE 4 Preferred Components of HC CDR3 Preferred Fraction of Adjusted Component Length Complexity Library Fraction 1 YYCA21111YFDYWG. 8 2.6 .times. 10.sup.5 .10 .02 (1 = any amino acid residue, except C; 2 = K and R) 2 YYCA2111111YFDYWG. 10 9.4 .times. 10.sup.7 .14 .14 (1 = any amino acid residue, except C; 2 = K and R 3 YYCA211111111YFDYTG. 12 3.4 .times. 10.sup.10 .25 .25 (1 = any amino acid residue, except C; 2 = K and R 4 YYCAR111S2S3111YFDYWG. 14 1.9 .times. 10.sup.8 .13 .14 (1 = any amino acid residue, except C; 2 = S and G 3 = Y and W) 5 YYCA2111CSG11CY1YFDYWG. 15 9.4 .times. 10.sup.7 .13 .14 (1 = any amino acid residue, except C; 2 = K and R 6 YYCA211S1TIFG11111YFDYWG. 17 1.7 .times. 10.sup.10 .11 .12 (1 = any amino acid residue, except C; 2 = K and R 7 YYCAR111YY2S33YY111YFDYWG. 18 3.8 .times. 10.sup.8 .04 .08 (1 = any amino acid residue, except C; 2 = D or G; 3 = S and G) 8 YYCAR1111YC2231CY111YFDYWG. 19 2.0 .times. 10.sup.11 .10 .11 (1 = any amino acid residue, except C; 2 = S and G; 3 = T, D and G)

[0162] TABLE-US-00005 TABLE 5 Oligonucleotides used to variegate the eight components of HC CDR3 (Ctop25): 5'-gctctggtcaac|tta|agg|gct|gag|g-3' (CtprmA): 5'-gctctggtcaac|tta|agg|gct|gag|gac|acc|gct|gtc|tac|tac|tgc|gcc-- 3' AflII... (CBprmB) [RC]: 5'-|tac|ttc|gat|tac|tgg|ggc|caa|ggt|acc|ctg|gtc|acc|tcgctccacc-3' BstEII... (CBot25) [RC]: 5'-|ggt|acc|ctg|gtc|acc|tcgctccacc-3' The 20 bases at 3' end of CtprmA are identical to the most 5' 20 bases of each of the vgDNA molecules. Ctop25 is identical to the most 5' 25 bases of CtprmA. The 23 most 3' bases of CBprmB are the reverse complement of the most 3' 23 bases of each of the vgDNA molecules. CBot25 is identical to the 25 bases at the 5' end of CBprmB. Component 1 (C1t08): 5'-cc|gct|gtc|tac|tac|tgc|ggc|<2>|<1>|<1>|<1- >|<1>|tac|ttc|gat|tac|tgg|ggc|caa|gg-3' Component 2 (C2t10): 5'-cc|gct|gtc|tac|tac|tgc|gcc|<2>|<1>|<1>|<1- >|<1>|<1>|<1>|tac|ttc|gat|tac|tgg|ggc|caa|gg-3' Component 3 (C3t12): 5'-cc|gct|gtc|tac|tac|tgc|gcc|<2>|<1>|<1>|<1- >|<1>|<1>|<1>|<1>|<1>|tac|ttc||gat|tac|- tgg|ggc|caa|gg-3' Component 4 (C4t140): 5'-cc|gct|gtc|tac|tac|tgc|gcc|cgt|<1>|<1>|<1>|- tct|<2>|tct|<3>|<1>|<1>|<1>|tac|ttc|gat|- tac|tgg|ggc|caa|gg-3' Component 5 (C5t15): 5'-cc|gct|gtc|tac|tac|tgc|gcc|<2>|<1>|<1>|<1- >|tgc|tct|ggt|<1>|<1>|tgc|tat|<1>|tac|- ttc|gat|tac|tgg|ggc|caa|gg-3' Component 6 (C6t17): 5'-cc|gct|gtc|tac|tac|tgc|gcc|<2>|<1>|<1>|tct&l- t;1>|act|atc|ttc|ggt|<1>|<1>|<1>|<1>|- <1>|tac|ttc|gat|tac|tgg|ggc|caa|gg-3' Component 7 (C7t18): 5'-cc|gct|gtc|tac|tac|tgc|ggc|cgt|<1>|<1>|<1>|t- at|tac|<2>|tct|<3>|<3>|tac|tat|- <1>|<1>|<1>|tac|ttc|gat|tac|tgg|ggc|caa|gg-3' Component 8 (c8t19): 5'-cc|gct|gtc|tac|tac|tgc|gcc|cgt|<1>|<1>|<1>|&- lt;1>|tat|tgc|<2>|<2>|<3>|<1>|tgc|tat|- <1>|<1>|<1>|tac|ttc|gat|tac|tgg|ggc|caa|gg-3' <1> = 0.095 Y + 0.095 G + 0.048 each of the residues ADEFHIKLMNPQRSTVW, no C; <2> = K and R (equimolar mixture) <1> = 0.095 Y + 0.095 G + 0.048 each of ADEFHIKLMNPQRSTVW, no C; <2> = K and R (equimolar mixture) <1> = 0.095 Y + 0.095 G + 0.048 each of ADEFHIKLMNPQRSTVW, no C; <2> = K and R (equimolar mixture) <1> = 0.095 Y + 0.095 G + 0.048 each of ADEFHIKLMNPQRSTVW, no C; <2> = S and G (equimolar mixture); <3> = Y and W (equimolar mixture) <1> = 0.095 Y + 0.095 G + 0.048 each of ADEFHIKLMNPQRSTVW, no C; <2> = K and R (equimolar mixture) <1> = 0.095 Y + 0.095 G + 0.048 each of ADEFHIKLMNPQRSTVW, no C; <2> = K and R (equimolar mixture) <1> = 0.095 Y + 0.095 G + 0.048 each of ADEFHIKLMNPQRSTVW, no C; <2> = D and G (equimolar mixture); <3> = S and G (equimolar mixture) <1> = 0.095 Y + 0.095 G + 0.048 each of ADEFHIKLMNPQRSTVW, no C; <2> = S and G (equimolar mixture); <3> = TDG (equimolar mixture);

[0163] TABLE-US-00006 TABLE 6 3-23::JH4 Stuffers in place of CDRs FR1 (DP47/V3-23) 20 21 22 23 24 25 26 27 28 29 30 A M A E V Q L L E S G ctgtctgaac cc atg gcc gaa|gtt|caa|ttg|tta|gag|tct|ggt| Scab...... NcoI.... MfeI --------------FR1-------------------------------------------- 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 G G L V Q P G G S L R L S C A |ggc|ggt|ctt|gtt|cag|cct|ggt|ggt|tct|tta|cgt|ctt|tct|tgc|gct| ----FR1-------------------->|...CDR1 stuffer....|---FR2------ 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 A S G F T F S S Y A | | W V R |gct|tcc|gaa|ttc|act|ttc|tct|tcg|tac|gct|tag|taa|tgg|gtt|cgc| BspEI BsiWI BstXI. -------FR2-------------------------------->|...CDR2 stuffer. 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 Q A P G K G L E W V S | p r | |caa|gct|cct|ggt|aaa|ggt|ttg|gag|tgg|gtt|tct|taa|cct|agg|tag| ... BstXI AvrII.. ...CDR2 stuffer....................................|---FR3--- 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 T I S R D N S K N T L Y L Q M |act|atc|tct|aga|gac|aac|tct|aag|aat|act|ctc|tac|ttg|cag|atg| XbaI ---FR3-----------..> CDR3 Stuffer------------->| 106 107 108 109 110 N S L R A |aac|agc|tta|agg|gct|tag taa agg cct taa AflII StuI... |----- FR4 ---(JH4)------------------------------------------ Y F D Y W G Q G T L V T V S S |tat|ttc|gat|tat|tgg|ggt|caa|ggt|acc|ctg|gtc|acc|gtc|tct|agt| KpnI BstEII

[0164] TABLE-US-00007 TABLE 7 A27:JH1 Human Kappa light chain gene gaggacc attgggcccc ctccgagact ctcgagcgca Scab...... Eco0109I XhoI.. ApaI. acgcaattaa tgtgagttag ctcactcatt aggcacccca ggctttacac tttatgcttc ..-35.. Plac ..-10. cggctcgtat gttgtgtgga attgtgagcg gataacaatt tcacacagga aacagctatg accatgatta cgccaagctt tggagccttt tttttggaga ttttcaac Pf1MI....... Hind III M13 III signal sequence (AA se|)--------------------------> 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 M K K L L F A I P L V V P F Y gtg aag aag ctc cta ttt gct atc ccg ctt gtc gtt ccg ttt tac -- Signal-->FR1------------------------------------------> 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 S H S A Q S V L T Q S P G T L |agc|cat|agt|gca|caa|tcc|gtc|ctt|act|caa|tct|cct|ggc|act|ctt| ApaLI... ----- FR1 ------------------------------------->| CDR1------> 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 S L S P G E R A T L S C R A S |tcg|cta|agc|ccg|ggt|gaa|cgt|gct|acc|tta|agt|tgc|cgt|gct|tcc| EspI..... AflII... XmaI.... (CDR1 installed as AflII-(SexAI or KasI) cassette.) For the most preferred 11 length codon 51 (XXX) is omitted; for the preferred 12 length this codon is <2> -------- CDR1 --------------------->|--- FR2 --------------> <1> <2> <2> xxx <3> 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Q - V - - - - L A W Y Q Q K P |cag| - |gtt| - | - | - | - |ctt|gct|tgg|tat|caa|cag|aaa|cct| SexAI... CDR2 installed as (SexAI or KasI) to (BamHI or RsrII) cassette.) ---- FR2 ------------------------->|------- CDR2 ----------> <1> <2> <4> 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 G Q A P R L L I Y - A S - R - |ggt|cag|gcg|ccg|cgt|tta|ctt|att|tat| - |gct|tct| - |cgc| - | SexAI.... KasI.... CDR2-->|--- FR3 -------------------------------------------> <1> 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 - G I P D R F S G S G S G T D | - |ggg|atc|ccg|gac|cgt|ttc|tct|ggc|tct|ggt|tca|ggt|act|gac| BamHI... RsrII..... ------ FR3 ------------------------------------------------> 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 F T L T I S R L E P E D F A V |ttt|acc|ctt|act|att|tct|aga|ttg|gaa|cct|gaa|gac|ttc|gct|gtt| XbaI... For CDR3 (Length 8): QQ33111P 1 and 3 as defined for Length 9 For CDR3 (Length 10): QQ3211PP1T 1 and 3 as defined for Length 9 2 S (0.2) and 0.044 each of ADEFGHIKLMNPQRTVWY CDR3 installed as XbaI to (StyI or BsiWI) cassette. ----------->|----CDR3-------------------------->|-----FR4---> <3> <1> <1> <1> <1> 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 Y Y C Q Q - - - - P - T F G Q |tat|tat|tgc|caa|cag| - | - | - | - |cct| - |act|ttc|ggt|caa| BstXI.......... -----FR4------------------->| <-------- Ckappa ----------- 121 122 123 124 125 126 127 128 129 130 131 132 133 134 G T K V E I K R T V A A P S |gt|acc|aag|gtt|gaa|atc|aag| |cgt|acg|gtt|gcc|gct|cct|agt| StyI.... BsiWI.. 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 V F I F P P S D E Q L K S G T |gtg|ttt|atc|ttt|cct|cct|tct|gac|gaa|caa|ttg|aag|tca|ggt|act| MfeI... 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 A S V V C L L N N F Y P R E A |gct|tct|gtc|gta|tgt|ttg|ctc|aac|aat|ttc|tac|cct|cgt|gaa|gct| BssSI... 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 K V Q W K V D N A L Q S G N S |aaa|gtt|cag|tgg|aaa|gtc|gat|aac|gcg|ttg|cag|tcg|ggt|aac|agt| MluI.... 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 Q E S V T E Q D S K D S T Y S |caa|gaa|tcc|gtc|act|gaa|cag|gat|agt|aag|gac|tct|acc|tac|tct| 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 L S S T L T L S K A D Y E K H |ttg|tcc|tct|act|ctt|act|tta|tca|aag|gct|gat|tat|gag|aag|cat| 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 K V Y A C E V T H Q G L S S P |aag|gtc|tat|GCt|TGC|gaa|gtt|acc|cac|cag|ggt|ctg|agc|tcc|cct| SacI.... 225 226 227 228 229 230 231 232 233 234 V T K S F N R G E C . . |gtt|acc|aaa|agt|ttc|aac|cgt|ggt|gaa|tgc|taa|tag ggcgcgcc DsaI.... AscI.... BssHII acgcatctctaa gcggccgc aacaggaggag NotI.... For CDR1: <1> ADEFGHIKLMNPQRSTVWY 1:1 <2> S (0.2) ADEFGHIKLMNPQRTVWY (0.044 each) <3> Y (0.2) ADEFGHIKLMNPQRSTVW (0.044 each) For CDR2: <1> ADEFGHIKLMNPQRSTVWY 1:1 <2> S (0.2) ADEFGHIKLMNPQRTVWY (0.044 each) <4> A (0.2) DEFGHIKLMNPQRSTVWY (0.044 each) For CDR3 (Length 9): <1> ADEFGHIKLMNPQRSTVWY 1:1 <3> Y (0.2) ADEFGHIKLMNPQRTVW (0.044 each)

[0165] TABLE-US-00008 TABLE 8 2a2 JH2 Human lambda-chain gene gaggaccatt gggcccc ttactccgtgac Scab...... Eco0109I ApaI.. -----------FR1--------------------------------------------> 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 S A Q S A L T Q P A S V S G S P G agt|gca|caa|tcc|gct|ctc|act|cag|cct|gct|agc|gtt|tcc|ggg|tca|cct|ggt| ApaLI... NheI... BstEII... SexAI..... T G <1> S S <2> V G ------FR1------------------> |-----CDR1-------------------- 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Q S I T I S C T G - S S - V G |caa|agt|atc|act|att|tct|tgt|aca|ggt| - |tct|tct| - gtt|ggc| BsrGI.. <1> <3> <2> <3> V S = vg Scheme #1, length = 14 -----CDR1------------->|--------FR2------------------------- 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 - - - - V S W Y Q Q H P G K A | - | - | - | - |gtt|tct|tgg|tat|caa|caa|cac|ccg|ggc|aag|gcg| XmaI.... KasI AvaI.... <4> <4> <4> <2> R P S --FR2------------------> |------CDR2--------------->|----FR3- 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 P K L M I Y - - - - R P S G V |ccg|aag|ttg|atg|atc|tac| - | - | - | - |cgt|cct|tct|ggt|gtt| KasI.... FR3 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 S N R F S G S K S G N T A S L |agc|aat|cgt|ttc|tcc|gga|tct|aaa|tcc|ggt|aat|acc|gca|agc|tta| BspEI.. HindIII. BsaBI........(blunt) -------FR3------------------------------------------------->1 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 T I S G L Q A E D E A D Y Y C |act|atc|tct|ggt|ctg|cag|gct|gaa|gac|gag|gct|gac|tac|tat|tgt| PstI... <4> <5> <4> <2> <4> S <4> <4> <4> <4> V -----CDR3-------------------------------->|---FR4---------- 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 - - - - - S - - - - V F G G G | - | - | - | - | - |tct| - | - | - | - |gtc|ttc|ggc|ggt|ggt| KpnI... ------FR4--------------> 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 T K L T V L G Q P K A A P S V |acc|aaa|ctt|act|gtc|ctc|ggt|caa|cct|aag|gct|gct|cct|tcc|gtt| KpnI... HincII.. Bsu36I... 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 T L F P P S S E E L Q A N K A |act|ctc|ttc|cct|cct|agt|tct|gaa|gag|ctt|caa|gct|aac|aag|gct| SapI...... 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 T L V C L I S D F Y P G A V T |act|ctt|gtt|tgc|ttg|atc|agt|gac|ttt|tat|cct|ggt|gct|gtt|act| BclI.... 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 V A W K A D S S P V K A G V E |gtc|gct|tgg|aaa|gcc|gat|tct|tct|cct|gtt|aaa|gct|ggt|gtt|gag| BsmBI... 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 T T T P S K Q S N N K Y A A S |acg|acc|act|cct|tct|aaa|caa|tct|aac|aat|aag|tac|gct|gcg|agc| BsmBI.... SacI.... 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 S Y L S L T P E Q W K S H K S |tct|tat|ctt|tct|ctc|acc|cct|gaa|caa|tgg|aag|tct|cat|aaa|tcc| SacI... 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 Y S C Q V T H E G S T V E K T |tat|tcc|tgt|caa|gtt|act|cat|gaa|ggt|tct|acc|gtt|gaa|aag|act| BspHI... 211 212 213 214 215 216 217 218 219 V A P T E C S . . |gtt|gcc|cct|act|gag|tgt|tct|tag|tga|ggcgcgcc AscI.... BssHII aacgatgttc aag gcggccgc aacaggaggag NotI.... Scab....... For CDR1 (length 14): <1> = 0.27 T, 0.27 G, 0.027 each of ADEFHIKLMNPQRSVWY, no C <2> = 0.27 D, 0.27 N, 0.027 each of AEFGHIKLMPQRSTVWY, no C <3> = 0.36 Y, 0.0355 each of ADEFGHIKLMNPQRSTVW, no C A second Vg scheme for CDR1 gives segments of length 11: T.sub.22G<2><4>L<4><4><4><3><4>- <4> where <4> 32 e|uimolar mixture of each of ADEFGHIKLMNPQRSTVWY, no C <3> 32 as defined above for the alternative CDR1 For CDR2: <2> and <4> are the same variegation as for CDR1 CDR3 (Length 11): <2> and <4>are the same variegation as for CDR1 <5> = 0.36 S, 0.0355 each of ADEFGHIKLMNPQRTVWY no C CDR3 (Length 10): <5> SY <1> <5> S <5> <1> <4> V <1> is an equimolar mixture of ADEFGHIKLMNPQRSTVWY, no C <4> and <5> are as defined for Length 11

[0166] TABLE-US-00009 TABLE 9 Oligonucleotides For Kappa and Lambda Light Chain Variegation (Ctop25): 5'-gctctggtcaac|tta|agg|gct|gag|g-3' (CtprmA): 5'-gctctggtcaac|tta|agg|gct|gag|gac|acc|gct|gtc|tac|tac|tgc|gcc-- 3' AflII... (CBprmB) [RC]: 5'-|tac|ttc|gat|tac|ttg|ggc|caa|ggt|acc|ctg|gtc|acc|tcgctccacc-3' BstEII... (CBot25) [RC]: 5'-|ggt|acc|ctg|gtc|acc|tcgctccacc-3' Kappa chains: CDR1 ("1"), CDR2 ("2"), CDR3 ("3") CDR1 (Ka1Top610): 5'-ggtctcagttg|cta|agc|ccg|ggt|gaa|cgt|gct|acc|tta|agt|tgc|cgt|gct|tcc|ca- g-3' (Ka1STp615): 5'-ggtctcagttg|cta|agc|ccg|ggt|g-3' (Ka1Bot620) [RC]: 5'-ctt|gct|tgg|tat|caa|cag|aaa|cct|ggt|cag|gcg|ccaagtcgtgtc-3' (Ka1SB625) [RC]: 5'-cct|ggt|cag|gcg|ccaagtcgtgtc-3' (Ka1vg600): 5'-gct|acc|tta|agt|tgc|cgt|gct|tcc|cag- |<1>|gtt|<2>|<2>|<3>|ctt|gct|tgg|tat|caa|cag|aaa|- cc-3' (Ka1vg600-12): 5'-gct|acc|tta|agt|tgc|cgt|gct|tcc|cag- |<1>|gtt<2>|<2>|<2>|<3>|ctt|gct|tgg|tat|caa- |cag|aaa|cc-3' CDR2 (Ka2Tshort657): 5'-cacgagtccta|cct|ggt|cag|gc-3' (Ka2Tlong655): 5'-cacgagtccta|cct|ggt|cag|gdg|ccg|cgt|tta|ctt|att|tat-3' (Ka2Bshort660): [RC]: 5'-|gac|cgt|ttc|tct|ggt|tctcacc-3' |cgc|<4>|<1>|ggg|atc|ccg|gac|cgt|ttc|tct|ggt|tctcacc-3' CDR3 (Ka3Tlon672): 5'-gacgagtccttct|aga|ttg|gaa|cct|gaa|gac|ttc|gct|gtt|tat|tat|tgc|caa|c-3' (Ka3BotL682) [RC]: 5'-act|ttc|ggt|caa|ggt|acc|aag|gtt|gaa|atc|aag|cgt|acg|tcacaggtgag-3' (Ka3Bsho694) [RC]: 5'-gaa|atc|aag|cgt|acg|tcacaggtgag-3' (Ka3vg670): 5'-gac|ttc|gct|gtt|- |tat|tat|tgc|caa|cag|<3>|<1>|<1>a<1>|cct|<1&gt- ;|act|ttc|ggt|caa|- |ggt|acc|aag|gtt|g-3' (Ka3vg670-8): 5'-gac|ttc|gct|gtt|- |tat|tat|tgc|caa|cag|<3>|<3>|<1>|<1>|<1>|cc- t|ttc|ggt|caa|- |ggt|acc|aag|gtt|g-3' (Ka3vg670-10): 5'-gac|ttc|gct|gtt|tat|- |tat|tgc|caa|cag|<3>|<2>|<1>|<1>|cct|cct|<1&gt- ;|act|ttc|ggt|caa|- |ggt|acc|aag|gtt|g-3' Lambda Chains: CDR1 ("1"), CDR2 ("2"), CDR3 ("3") CDR1 (Lm1TPri75): 5'-gacgagtcctgg|tca|cct|ggt|-3' (Lm1tlo715): 5'-gacgagtcctgg|tca|cct|ggt|caa|agt|atc|act|att|tct|tgt|aca|ggt-3' (Lm1blo724) [rc]: 5'-gtt|tct|tgg|tat|caa|caa|cac|ccg|ggc|aag|gcg|agatcttcacaggtgag-3' (Lm1bsh737) [rc]: 5'-gc|aag|gcg|agatcttcacaggtgag-3' (Lm1vh710b): 5'-gt|atc|act|att|tct|tgt|aca|ggt|<2>|<4>|ctc|<4>|<4- >|<4>|- |<3>|<4>|<4>|tgg|tat|caa|caa|cac|cc-3-' (Lm1vh710): 5'-gt|atc|act|att|tct|tgt|aca|ggt|<1>|tct|tct|<2>|gtt|ggc|- |<1>|<3>|<2>|<3>|gtt|tct|tgg|tat|caa|caa|cac|cc-3- ' CDR2 (Lm2TSh757): 5'-gagcagaggac|ccg|ggc|aag|gc-3' (Lm2TLo753): 5'-gagcagaggac|ccg|ggc|aag|gcg|ccg|aag|ttg|atg|atc|tac|-3' (Lm2BLo762) [RC]: 5'-cgt|cct|tct|ggt|gtc|agc|aat|cgt|ttc|tcc|gga|tcacaggtgag-3' (Lm2BSh765) [RC]: 5'-cgt|ttc|tcc|gga|tcacaggtgag-3' (Lm2vg750): 5'-g|ccg|aag|ttg|atg|atc|tac|- <4>|<4>|<4>|<2>|cgt|cct|tct|ggt|gtc|agc|aat|c-3' CDR3 (Lm3TSh822): 5'-ctg|cag|gct|gaa|gac|gag|gct|gac-3' (Lm3TLo819): 5'-ctg|cag|gct|gaa|gac|gag|gct|gac|tac|tat|tgt|-3' (Lm3BLo825) [RC]: 5'-gtc|ttc|ggc|ggt|ggt|acc|aaa|ctt|act|gtc|ctc|ggt|caa|cct|aag|g- acacaggtgag-3' (Lm3BSh832) [RC]: 5'-c|ggt|caa|cct|aag|gacacaggtgag-3' (Lm3vg817): 5'-gac|gag|gct|gac|tac|tat|tgt|- |<4>|<5>|<4>|<2>|<4>|tct|<4>|<4&gt- ;|<4>|<4>|- Gtc|ttc|ggc|ggt|ggt|acc|aaa|ctt|ac-3' (Lm3vg817-10): 5'- gac|gag|gct|gac|tac|tat|tgt|- |<5>|agc|tat|<1>|<5>|tct<5>|<1>|<4>|g- tc|ttc|ggc|ggt|ggt|- |acc|aaa|ctt|ac-3'

[0167] TABLE-US-00010 TABLE 10 A27:JH1 Kappa light chain gene with stuffers in place of CDRs Each stuffer contains at least one stop codon and a restriction site that will be uni|ue within the diversity vector. gaggacc attgggcccc ctccgagact ctcgagcgca Scab.....Eco0109I ApaI. XhoI.. acgcaattaa tgtgagttag ctcactcatt aggcacccca ggctttacac tttatgcttc ..-35.. Plac ..-10. cggctcgtat gttgtgtgga attgtgagcg gataacaatt tcacacagga aacagctatgac catgatta cgccaagctt tggagccttt tttttggaga ttttcaac PflMI....... Hind3. M13 III signal se|uence (AA se|)--------------------------> 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 M K K L L F A I P L V V P F Y gtg aag aag ctc cta ttt gct atc ccg ctt gtc gtt ccg ttt tac --Signal--> FR1-------------------------------------------> 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 S H S A Q S V L T Q S P G T L |agc|cat|agt|gca|caa|tcc|gtc|ctt|act|caa|tct|cct|ggc|act|ctt| ApaLI... ----- FR1 --------------------------------->|-------Stuffer-> 31 32 33 34 35 36 37 38 39 40 41 42 43 S L S P G E R A T L S | | |tcg|cta|agc|ccg|ggt|gaa|cgt|gct|acc|tta|agt|tag|taa|gct|ccc| EspI..... AflII... XmaI.... - Stuffer for CDR1-->FR2 --------- FR2 ------>|-----------Stuffer for CDR2 59 60 61 62 63 64 65 66 K P G Q A P R |agg|cct|actt|tga|tct|g|aaa|cct|ggt|cag|gcg|ccg|cgt|taa|tga|aagcgctaatggcc- aacagtg StuI... SexAI... KasI.... AfeI.. MscI.. Stuffer-->|--- FR3 -----------------------------------------> 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 T G I P D R F S G S G S G T D |act|ggg|atc|ccg|gac|ccgt|ttc|tct|ggc|tct|ggt|tca|ggt|act|gac| BamHI... RsrII..... ------ FR3 ----->----------------STUFFER for CDR3-----------------> 91 92 93 94 95 96 97 F T L T I S R | | |ttt|acc|ctt|act|att|tct|aga|taa|tga| gttaac tag acc tacgta acc tag XbaI... HpaI.. SnaBI. -----------------CDR3 stuffer------------------>|-----FR4---> 118 119 120 F G Q |ttc|ggt|caa| -----FR4------------------->| <------ Ckappa ------------- 121 122 123 124 125 126 127 128 129 130 131 132 133 134 G T K V E I K R T V A A P S |ggt|acc|aag|gtt|gaa|atc|aag| |cgt|acg|gtt|gcc|gct|cct|agt| StyI.... BsiWI.. 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 V F I F P P S D E Q L K S G T |gtg|ttt|atc|ttt|cct|cct|tct|gac|gaa|caa|ttg|aag|tca|ggt|act| MfeI... acgcatctctaa gcggccgc aacaggaggag NotI.... EagI..

[0168] TABLE-US-00011 TABLE 11 2a2:JH2 Human lambda-chain gene with stuffers in place of CDRs gaggaccatt gggcccc ttactccgtgac Scab...... Eco0109I ApaI.. ----------FR1--------------------------------------------> 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 S A Q S A L T Q P A S V S G S P G agt|gca|caa|tcc|gct|ctc|act|cag|cct|gct|agc|gtt|tcc|ggg|tca|cct|ggt| ApaLI... NheI... BstEII... SexAI.... ------FR1------------------> |-----stuffer for CDR1--------- 16 17 18 19 20 21 22 23 Q S I T I S C T |caa|agt|atc|act|att|tct|tgt|aca|tct tag tga ctc BsrGI.. -----Stuffer--------------------------->-------FR2----------> 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 R S | | P | H P G K A aga tct taa tga ccg tag cac|ccg|ggc|aag|gcg| BglII XmaI.... KasI..... AvaI.... --|--------------Stuffer for CDR2 -----------------------------> P |ccg|taa|tga|atc tcg tac g ct|ggt|gtt| KasI.... BsiWI... -------FR3---------------------------------------------------- 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 S N R F S G S K S G N T A S L |agc|aat|cgt|ttc|tcc|gga|tct|aaa|tcc|ggt|aat|acc|gca|agc|tta| BspEI.. HindIII. BsaBI........(blunt) -------FR3------------->|--Stuffer for CDR3---------------->| 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 T I S G L Q |act|atc|tct|ggt|ctg|caglgtt ctg tag ttc caattg ctt tag tga ccc PstI... MfeI.. -----Stuffer------------------------------->|---FR4--------- 103 104 105 G G G |ggc|ggt|ggt| KpnI... ---------FR4--------------> 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 T K L T V L G Q P K A A P S V |acc|aaa|ctt|act|gtc|ctc|ggt|caa|cct|aag|gct|gct|cct|tcc|gtt| KpnI... HincII.. Bsu36I... 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 T L F P P S S E E L Q A N K A |act|ctc|ttc|cct|cct|agt|tct|gaa|gag|ctt|caa|gct|aac|aag|gct| SapI..... 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 T L V C L I S D F Y P G A V T |act|ctt|gtt|tgc|ttg|atc|agt|gac|ttt|tat|cct|ggt|gct|gtt|act| BclI....

[0169]

Sequence CWU 1

1

99 1 14 PRT Artificial Sequence Description of Artificial Sequence Heavy chain CDR1 vector 1 Val Ser Gly Gly Ser Ile Ser Xaa Xaa Xaa Tyr Tyr Trp Xaa 1 5 10 2 17 PRT Artificial Sequence Description of Artificial Sequence Heavy chain CDR2 vector 2 Xaa Ile Xaa Xaa Ser Gly Gly Xaa Thr Xaa Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly 3 17 PRT Artificial Sequence Description of Artificial Sequence Heavy chain CDR2 vector 3 Xaa Ile Xaa Xaa Xaa Gly Xaa Xaa Xaa Xaa Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly 4 16 PRT Artificial Sequence Description of Artificial Sequence Heavy chain CDR2 vector 4 Xaa Ile Xaa Xaa Xaa Gly Xaa Xaa Xaa Tyr Asn Pro Ser Leu Lys Gly 1 5 10 15 5 19 PRT Artificial Sequence Description of Artificial Sequence Heavy chain CDR2 vector 5 Xaa Ile Xaa Ser Xaa Xaa Xaa Gly Gly Tyr Tyr Xaa Tyr Ala Ala Ser 1 5 10 15 Val Lys Gly 6 15 PRT Artificial Sequence Description of Artificial Sequence Heavy chain CDR3 vector 6 Tyr Tyr Cys Ala Xaa Xaa Xaa Xaa Xaa Tyr Phe Asp Tyr Trp Gly 1 5 10 15 7 17 PRT Artificial Sequence Description of Artificial Sequence Heavy chain CDR3 vector 7 Tyr Tyr Cys Ala Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr Phe Asp Tyr Trp 1 5 10 15 Gly 8 19 PRT Artificial Sequence Description of Artificial Sequence Heavy chain CDR3 vector 8 Tyr Tyr Cys Ala Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr Phe Asp 1 5 10 15 Tyr Trp Gly 9 21 PRT Artificial Sequence Description of Artificial Sequence Heavy chain CDR3 vector 9 Tyr Tyr Cys Ala Arg Xaa Xaa Xaa Ser Xaa Ser Xaa Xaa Xaa Xaa Tyr 1 5 10 15 Phe Asp Tyr Trp Gly 20 10 22 PRT Artificial Sequence Description of Artificial Sequence Heavy chain CDR3 vector 10 Tyr Tyr Cys Ala Xaa Xaa Xaa Xaa Cys Ser Gly Xaa Xaa Cys Tyr Xaa 1 5 10 15 Tyr Phe Asp Tyr Trp Gly 20 11 24 PRT Artificial Sequence Description of Artificial Sequence Heavy chain CDR3 vector 11 Tyr Tyr Cys Ala Xaa Xaa Xaa Ser Xaa Thr Ile Phe Gly Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Tyr Phe Asp Tyr Trp Gly 20 12 25 PRT Artificial Sequence Description of Artificial Sequence Heavy chain CDR3 vector 12 Tyr Tyr Cys Ala Arg Xaa Xaa Xaa Tyr Tyr Xaa Ser Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Tyr Phe Asp Tyr Trp Gly 20 25 13 26 PRT Artificial Sequence Description of Artificial Sequence Heavy chain CDR3 vector 13 Tyr Tyr Cys Ala Arg Xaa Xaa Xaa Xaa Tyr Cys Xaa Xaa Xaa Xaa Cys 1 5 10 15 Tyr Xaa Xaa Xaa Tyr Phe Asp Tyr Trp Gly 20 25 14 11 PRT Artificial Sequence Description of Artificial Sequence Kappa light chain CDR1 vector 14 Arg Ala Ser Gln Xaa Val Xaa Xaa Xaa Leu Ala 1 5 10 15 12 PRT Artificial Sequence Description of Artificial Sequence Kappa light chain CDR1 vector 15 Arg Ala Ser Gln Xaa Val Xaa Xaa Xaa Xaa Leu Ala 1 5 10 16 9 PRT Artificial Sequence Description of Artificial Sequence Kappa light chain CDR3 vector 16 Gln Gln Xaa Xaa Xaa Xaa Pro Xaa Thr 1 5 17 10 PRT Artificial Sequence Description of Artificial Sequence Kappa light chain CDR3 vector 17 Gln Gln Xaa Xaa Xaa Xaa Pro Pro Xaa Thr 1 5 10 18 14 PRT Artificial Sequence Description of Artificial Sequence Lambda light chain CDR1 vector 18 Thr Gly Xaa Ser Ser Xaa Val Gly Xaa Xaa Xaa Xaa Val Ser 1 5 10 19 10 PRT Artificial Sequence Description of Artificial Sequence Lambda light chain CDR3 vector 19 Xaa Ser Tyr Xaa Xaa Ser Xaa Xaa Xaa Val 1 5 10 20 14 PRT Homo sapiens 20 Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Ser Ser 1 5 10 21 15 PRT Homo sapiens 21 Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 1 5 10 15 22 5 PRT Artificial Sequence Description of Artificial Sequence Synthetic peptide 22 Tyr Tyr Cys Ala Arg 1 5 23 323 DNA Artificial Sequence Description of Artificial Sequence 3-23 JH4 vector with CDR1/2 diversity 23 cc atg gcc gaa gtt caa ttg tta gag tct ggt ggc ggt ctt gtt cag 47 Ala Met Ala Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln 1 5 10 15 cct ggt ggt tct tta cgt ctt tct tgc gct gct tcc gga ttc act ttc 95 Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe 20 25 30 tct nnn tac nnn atg nnn tgg gtt cgc caa gct cct ggt aaa ggt ttg 143 Ser Xaa Tyr Xaa Met Xaa Trp Val Arg Gln Ala Pro Gly Lys Gly Leu 35 40 45 gag tgg gtt tct nnn atc nnn nnn tct ggt ggc nnn act nnn tat gct 191 Glu Trp Val Ser Xaa Ile Xaa Xaa Ser Gly Gly Xaa Thr Xaa Tyr Ala 50 55 60 gac tcc gtt aaa ggt cgc ttc act atc tct aga gac aac tct aag aat 239 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn 65 70 75 80 act ctc tac ttg cag atg aac agc tta agg gct gag gac acc gct gtc 287 Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val 85 90 95 tac tac tgc gcc aaa gac tat gaa ggt act ggt tat 323 Tyr Tyr Cys Ala Lys Asp Tyr Glu Gly Thr Gly Tyr 100 105 24 108 PRT Artificial Sequence Description of Artificial Sequence 3-23 JH4 vector with CDR1/2 diversity 24 Ala Met Ala Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln 1 5 10 15 Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe 20 25 30 Ser Xaa Tyr Xaa Met Xaa Trp Val Arg Gln Ala Pro Gly Lys Gly Leu 35 40 45 Glu Trp Val Ser Xaa Ile Xaa Xaa Ser Gly Gly Xaa Thr Xaa Tyr Ala 50 55 60 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn 65 70 75 80 Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val 85 90 95 Tyr Tyr Cys Ala Lys Asp Tyr Glu Gly Thr Gly Tyr 100 105 25 45 DNA Homo sapiens CDS (1)..(45) 25 tat ttc gat tat tgg ggt caa ggt acc ctg gtc acc gtc tct agt 45 Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 1 5 10 15 26 15 PRT Homo sapiens 26 Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 1 5 10 15 27 55 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 27 cttccggatt cactttctct nnntacnnna tgnnntgggt tcgccaagct cctgg 55 28 28 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 28 cctactgtct tccggattca ctttctct 28 29 30 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 29 tgggttcgcc aagctcctgg ttgctcactc 30 30 61 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 30 cttccggatt cactttctct wsnnnnnnnt actactggnn ntgggttcgc caagctcctg 60 g 61 31 82 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 31 cttccggatt cactttctct atcagcggtg gttctatctc cnnnnnnnnn tactactggn 60 nntgggttcg ccaagctcct gg 82 32 68 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 32 ggtttggagt gggtttctnn natcnnnnsn tctggtggcn nnactnnnta tgctgactcc 60 gttaaagg 68 33 44 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 33 cttgggttcg ccaagctcct ggtaaaggtt tggagtgggt ttct 44 34 49 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 34 tatgctgact ccgttaaagg tcgcttcact atctctagat tcctgtcac 49 35 68 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 35 ggtttggagt gggtttctnn natcdnnnnn nnnggtdvnn nnnnnnnnta tgctgactcc 60 gttaaagg 68 36 65 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 36 ggtttggagt gggtttctnn natcdnnnnn nnnggtdvnn nnnnntataa cccttccctt 60 aaggg 65 37 49 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 37 tataaccctt cccttaaggg tcgcttcact atctctagat tcctgtcac 49 38 74 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 38 ggtttggagt gggtttctnn natcnnnagt nnnnnnnnng gtggtactac tnnntatgcc 60 gcttccgtta aggg 74 39 49 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 39 tatgccgctt ccgttaaggg tcgcttcact atctctagat tcctgtcac 49 40 25 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 40 gctctggtca acttaagggc tgagg 25 41 48 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 41 gctctggtca acttaagggc tgaggacacc gctgtctact actgcgcc 48 42 46 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 42 tacttcgatt actggggcca aggtaccctg gtcacctcgc tccacc 46 43 25 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 43 ggtaccctgg tcacctcgct ccacc 25 44 58 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 44 ccgctgtcta ctactgcgcc mrnnnnnnnn nnnnntactt cgattactgg ggccaagg 58 45 64 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 45 ccgctgtcta ctactgcgcc mrnnnnnnnn nnnnnnnnnn ntacttcgat tactggggcc 60 aagg 64 46 70 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 46 ccgctgtcta ctactgcgcc mrnnnnnnnn nnnnnnnnnn nnnnnnntac ttcgattact 60 ggggccaagg 70 47 76 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 47 ccgctgtcta ctactgcgcc cgtnnnnnnn nntctdsntc ttrbnnnnnn nnntacttcg 60 attactgggg ccaagg 76 48 79 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 48 ccgctgtcta ctactgcgcc mrnnnnnnnn nntgctctgg tnnnnnntgc tatnnntact 60 tcgattactg gggccaagg 79 49 85 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 49 ccgctgtcta ctactgcgcc mrnnnnnnnt ctnnnactat cttcggtnnn nnnnnnnnnn 60 nntacttcga ttactggggc caagg 85 50 88 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 50 ccgctgtcta ctactgcgcc cgtnnnnnnn nntattacgr ntctdsndsn tactatnnnn 60 nnnnntactt cgattactgg ggccaagg 88 51 91 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 51 ccgctgtcta ctactgcgcc cgtnnnnnnn nnnnntattg cdsndsnrvn nnntgctatn 60 nnnnnnnnta cttcgattac tggggccaag g 91 52 242 DNA Artificial Sequence Description of Artificial Sequence 3-23 JH4 vector with stuffers 52 cc atg gcc gaa gtt caa ttg tta gag tct ggt ggc ggt ctt gtt cag 47 Ala Met Ala Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln 1 5 10 15 cct ggt ggt tct tta cgt ctt tct tgc gct gct tcc gga ttc act ttc 95 Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe 20 25 30 tct tcg tac gct tagtaa tgg gtt cgc caa gct cct ggt aaa ggt ttg 143 Ser Ser Tyr Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu 35 40 45 gag tgg gtt tct taa cct agg tag act atc tct aga gac aac tct aag 191 Glu Trp Val Ser Pro Arg Thr Ile Ser Arg Asp Asn Ser Lys 50 55 60 aat act ctc tac ttg cag atg aac agc tta agg gct tagtaaaggc cttaa 242 Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala 65 70 53 72 PRT Artificial Sequence Description of Artificial Sequence 3-23 JH4 vector with stuffers 53 Ala Met Ala Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln 1 5 10 15 Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe 20 25 30 Ser Ser Tyr Ala Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp 35 40 45 Val Ser Pro Arg Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 50 55 60 Leu Gln Met Asn Ser Leu Arg Ala 65 70 54 952 DNA Homo sapiens CDS (206)..(907) modified_base (344)..(346) a, c, t, g, other or unknown 54 gaggaccatt gggccccctc cgagactctc gagcgcaacg caattaatgt gagttagctc 60 actcattagg caccccaggc tttacacttt atgcttccgg ctcgtatgtt gtgtggaatt 120 gtgagcggat aacaatttca cacaggaaac agctatgacc atgattacgc caagctttgg 180 agcctttttt ttggagattt tcaac gtg aag aag ctc cta ttt gct atc ccg 232 Met Lys Lys Leu Leu Phe Ala Ile Pro 1 5 ctt gtc gtt ccg ttt tac agc cat agt gca caa tcc gtc ctt act caa 280 Leu Val Val Pro Phe Tyr Ser His Ser Ala Gln Ser Val Leu Thr Gln 10 15 20 25 tct cct ggc act ctt tcg cta agc ccg ggt gaa cgt gct acc tta agt 328 Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser 30 35 40 tgc cgt gct tcc cag nnn gtt nnn nnn nnn nnn ctt gct tgg tat caa 376 Cys Arg Ala Ser Gln Xaa Val Xaa Xaa Xaa Xaa Leu Ala Trp Tyr Gln 45 50 55 cag aaa cct ggt cag gcg ccg cgt tta ctt att tat nnn gct tct nnn 424 Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Xaa Ala Ser Xaa 60 65 70 cgc nnn nnn ggg atc ccg gac cgt ttc tct ggc tct ggt tca ggt act 472 Arg Xaa Xaa Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr 75 80 85 gac ttt acc ctt act att tct aga ttg gaa cct gaa gac ttc gct gtt 520 Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro Glu Asp Phe Ala Val 90 95 100 105 tat tat tgc caa cag nnn nnn nnn nnn cct nnn act ttc ggt caa ggt 568 Tyr Tyr Cys Gln Gln Xaa Xaa Xaa Xaa Pro Xaa Thr Phe Gly Gln Gly 110 115 120 acc aag gtt gaa atc aag cgt acg gtt gcc gct cct agt gtg ttt atc 616 Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile 125 130 135 ttt cct cct tct gac gaa caa ttg aag tca ggt act gct tct gtc gta 664 Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val 140 145 150 tgt ttg ctc aac aat ttc tac cct cgt gaa gct aaa gtt cag tgg aaa 712 Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys 155 160 165 gtc gat aac gcg ttg cag tcg ggt aac agt caa gaa tcc gtc act gaa 760 Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu 170 175 180 185 cag gat agt aag gac tct acc tac tct ttg tcc tct act ctt act tta 808 Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu 190 195 200 tca aag gct gat tat gag aag cat aag gtc tat gct tgc gaa gtt acc 856 Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr 205 210 215 cac cag ggt ctg agc tcc cct gtt acc aaa agt ttc aac cgt ggt gaa 904 His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu 220 225 230 tgc taatagggcg cgccacgcat ctctaagcgg ccgcaacagg aggag 952 Cys 55 234 PRT Homo sapiens MOD_RES (47) Any amino acid 55 Met Lys Lys Leu Leu Phe Ala Ile Pro Leu Val Val Pro Phe Tyr Ser 1 5 10 15 His Ser Ala Gln Ser Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu 20 25 30 Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Xaa Val

35 40 45 Xaa Xaa Xaa Xaa Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro 50 55 60 Arg Leu Leu Ile Tyr Xaa Ala Ser Xaa Arg Xaa Xaa Gly Ile Pro Asp 65 70 75 80 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 85 90 95 Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Xaa Xaa 100 105 110 Xaa Xaa Pro Xaa Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 115 120 125 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 130 135 140 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 145 150 155 160 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 165 170 175 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 180 185 190 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 195 200 205 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 210 215 220 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 225 230 56 732 DNA Homo sapiens CDS (30)..(686) modified_base (108)..(110) a, c, t, g, other or unknown 56 gaggaccatt gggcccctta ctccgtgac agt gca caa tcc gct ctc act cag 53 Ser Ala Gln Ser Ala Leu Thr Gln 1 5 cct gct agc gtt tcc ggg tca cct ggt caa agt atc act att tct tgt 101 Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys 10 15 20 aca ggt nnn tct tct nnn gtt ggc nnn nnn nnn nnn gtt tct tgg tat 149 Thr Gly Xaa Ser Ser Xaa Val Gly Xaa Xaa Xaa Xaa Val Ser Trp Tyr 25 30 35 40 caa caa cac ccg ggc aag gcg ccg aag ttg atg atc tac nnn nnn nnn 197 Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Xaa Xaa Xaa 45 50 55 nnn cgt cct tct ggt gtt agc aat cgt ttc tcc gga tct aaa tcc ggt 245 Xaa Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly 60 65 70 aat acc gca agc tta act atc tct ggt ctg cag gct gaa gac gag gct 293 Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala 75 80 85 gac tac tat tgt nnn nnn nnn nnn nnn tct nnn nnn nnn nnn gtc ttc 341 Asp Tyr Tyr Cys Xaa Xaa Xaa Xaa Xaa Ser Xaa Xaa Xaa Xaa Val Phe 90 95 100 ggc ggt ggt acc aaa ctt act gtc ctc ggt caa cct aag gct gct cct 389 Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro 105 110 115 120 tcc gtt act ctc ttc cct cct agt tct gaa gag ctt caa gct aac aag 437 Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys 125 130 135 gct act ctt gtt tgc ttg atc agt gac ttt tat cct ggt gct gtt act 485 Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr 140 145 150 gtc gct tgg aaa gcc gat tct tct cct gtt aaa gct ggt gtt gag acg 533 Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr 155 160 165 acc act cct tct aaa caa tct aac aat aag tac gct gcg agc tct tat 581 Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr 170 175 180 ctt tct ctc acc cct gaa caa tgg aag tct cat aaa tcc tat tcc tgt 629 Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Lys Ser Tyr Ser Cys 185 190 195 200 caa gtt act cat gaa ggt tct acc gtt gaa aag act gtt gcc cct act 677 Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr 205 210 215 gag tgt tct tagtgaggcg cgccaacgat gttcaaggcg gccgcaacag gaggag 732 Glu Cys Ser 57 219 PRT Homo sapiens MOD_RES (27) Any amino acid 57 Ser Ala Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro 1 5 10 15 Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Xaa Ser Ser Xaa Val Gly 20 25 30 Xaa Xaa Xaa Xaa Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro 35 40 45 Lys Leu Met Ile Tyr Xaa Xaa Xaa Xaa Arg Pro Ser Gly Val Ser Asn 50 55 60 Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser 65 70 75 80 Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Xaa Xaa Xaa Xaa 85 90 95 Xaa Ser Xaa Xaa Xaa Xaa Val Phe Gly Gly Gly Thr Lys Leu Thr Val 100 105 110 Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser 115 120 125 Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser 130 135 140 Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser 145 150 155 160 Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn 165 170 175 Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp 180 185 190 Lys Ser His Lys Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr 195 200 205 Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 58 25 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 58 gctctggtca acttaagggc tgagg 25 59 48 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 59 gctctggtca acttaagggc tgaggacacc gctgtctact actgcgcc 48 60 46 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 60 tacttcgatt acttgggcca aggtaccctg gtcacctcgc tccacc 46 61 25 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 61 ggtaccctgg tcacctcgct ccacc 25 62 56 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 62 ggtctcagtt gctaagcccg ggtgaacgtg ctaccttaag ttgccgtgct tcccag 56 63 24 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 63 ggtctcagtt gctaagcccg ggtg 24 64 45 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 64 cttgcttggt atcaacagaa acctggtcag gcgccaagtc gtgtc 45 65 24 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 65 cctggtcagg cgccaagtcg tgtc 24 66 65 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 66 gctaccttaa gttgccgtgc ttcccagnnn gttnnnnnnn nncttgcttg gtatcaacag 60 aaacc 65 67 68 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 67 gctaccttaa gttgccgtgc ttcccagnnn gttnnnnnnn nnnnncttgc ttggtatcaa 60 cagaaacc 68 68 22 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 68 cacgagtcct acctggtcag gc 22 69 41 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 69 cacgagtcct acctggtcag gcgccgcgtt tacttattta t 41 70 22 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 70 gaccgtttct ctggttctca cc 22 71 76 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 71 caggcgccgc gtttacttat ttatnnngct tctnnncgcn nnnnngggat cccggaccgt 60 ttctctggtt ctcacc 76 72 53 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 72 gacgagtcct tctagattgg aacctgaaga cttcgctgtt tattattgcc aac 53 73 50 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 73 actttcggtc aaggtaccaa ggttgaaatc aagcgtacgt cacaggtgag 50 74 26 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 74 gaaatcaagc gtacgtcaca ggtgag 26 75 70 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 75 gacttcgctg tttattattg ccaacagnnn nnnnnnnnnc ctnnnacttt cggtcaaggt 60 accaaggttg 70 76 67 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 76 gacttcgctg tttattattg ccaacagnnn nnnnnnnnnn nncctttcgg tcaaggtacc 60 aaggttg 67 77 73 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 77 gacttcgctg tttattattg ccaacagnnn nnnnnnnnnc ctcctnnnac tttcggtcaa 60 ggtaccaagg ttg 73 78 21 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 78 gacgagtcct ggtcacctgg t 21 79 48 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 79 gacgagtcct ggtcacctgg tcaaagtatc actatttctt gtacaggt 48 80 50 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 80 gtttcttggt atcaacaaca cccgggcaag gcgagatctt cacaggtgag 50 81 25 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 81 gcaaggcgag atcttcacag gtgag 25 82 67 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 82 gtatcactat ttcttgtaca ggtnnnnnnc tcnnnnnnnn nnnnnnnnnn tggtatcaac 60 aacaccc 67 83 76 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 83 gtatcactat ttcttgtaca ggtnnntctt ctnnngttgg cnnnnnnnnn nnngtttctt 60 ggtatcaaca acaccc 76 84 22 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 84 gagcagagga cccgggcaag gc 22 85 41 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 85 gagcagagga cccgggcaag gcgccgaagt tgatgatcta c 41 86 44 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 86 cgtccttctg gtgtcagcaa tcgtttctcc ggatcacagg tgag 44 87 23 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 87 cgtttctccg gatcacaggt gag 23 88 53 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 88 gccgaagttg atgatctacn nnnnnnnnnn ncgtccttct ggtgtcagca atc 53 89 24 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 89 ctgcaggctg aagacgaggc tgac 24 90 33 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 90 ctgcaggctg aagacgaggc tgactactat tgt 33 91 57 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 91 gtcttcggcg gtggtaccaa acttactgtc ctcggtcaac ctaaggacac aggtgag 57 92 25 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 92 cggtcaacct aaggacacag gtgag 25 93 77 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 93 gacgaggctg actactattg tnnnnnnnnn nnnnnntctn nnnnnnnnnn ngtcttcggc 60 ggtggtacca aacttac 77 94 74 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 94 gacgaggctg actactattg tnnnagctat nnnnnntctn nnnnnnnngt cttcggcggt 60 ggtaccaaac ttac 74 95 627 DNA Artificial Sequence Description of Artificial Sequence A27 JH1 Kappa light chain gene with stuffers 95 gaggaccatt gggccccctc cgagactctc gagcgcaacg caattaatgt gagttagctc 60 actcattagg caccccaggc tttacacttt atgcttccgg ctcgtatgtt gtgtggaatt 120 gtgagcggat aacaatttca cacaggaaac agctatgacc atgattacgc caagctttgg 180 agcctttttt ttggagattt tcaac gtg aag aag ctc cta ttt gct atc ccg 232 Met Lys Lys Leu Leu Phe Ala Ile Pro 1 5 ctt gtc gtt ccg ttt tac agc cat agt gca caa tcc gtc ctt act caa 280 Leu Val Val Pro Phe Tyr Ser His Ser Ala Gln Ser Val Leu Thr Gln 10 15 20 25 tct cct ggc act ctt tcg cta agc ccg ggt gaa cgt gct acc tta agt 328 Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser 30 35 40 tagtaagctc ccaggcctct ttgatctg aaa cct ggt cag gcg ccg cgt 377 Lys Pro Gly Gln Ala Pro Arg 45 taatgaaagc gctaatggcc aacagtg act ggg atc ccg gac cgt ttc tct ggc 431 Thr Gly Ile Pro Asp Arg Phe Ser Gly 50 55 tct ggt tca ggt act gac ttt acc ctt act att tct aga taatgagtta 480 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg 60 65 70 actagaccta cgtaacctag ttc ggt caa ggt acc aag gtt gaa atc aag cgt 533 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 75 80 acg gtt gcc gct cct agt gtg ttt atc ttt cct cct tct gac gaa caa 581 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 85 90 95 ttg aag tca ggt act acgcatctct aagcggccgc aacaggagga g 627 Leu Lys Ser Gly Thr 100 96 102 PRT Artificial Sequence Description of Artificial Sequence A27 JH1 Kappa light chain gene with stuffers 96 Met Lys Lys Leu Leu Phe Ala Ile Pro Leu Val Val Pro Phe Tyr Ser 1 5 10 15 His Ser Ala Gln Ser Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu 20 25 30 Ser Pro Gly Glu Arg Ala Thr Leu Ser Lys Pro Gly Gln Ala Pro Arg 35 40 45 Thr Gly Ile Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe 50 55 60 Thr Leu Thr Ile Ser Arg Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 65 70 75 80 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 85 90 95 Gln Leu Lys Ser Gly Thr 100 97 413 DNA Artificial Sequence Description of Artificial Sequence 2a2 JH2 Human lambda-chain gene with stuffers in place of CDRs 97 gaggaccatt gggcccctta ctccgtgac agt gca caa tcc gct ctc act cag 53 Ser Ala Gln Ser Ala Leu Thr Gln 1 5 cct gct agc gtt tcc ggg tca cct ggt caa agt atc act att tct tgt 101 Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys 10 15 20 aca tcttagtgac tc aga tct taatga ccg tag cac ccg ggc aag gcg 149 Thr Arg Ser Pro His Pro Gly Lys Ala 25 30 ccg taatgaatct cgtacgctgg tgtt agc aat cgt ttc tcc gga tct aaa 200 Pro Ser Asn Arg Phe Ser Gly Ser Lys 35 40 tcc ggt aat acc gca agc tta act atc tct ggt ctg cag gttctgtagt 249 Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln 45 50 55 tccaattgct ttagtgaccc ggc ggt ggt acc aaa ctt act gtc ctc ggt caa 302 Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln 60 65 cct aag gct gct cct tcc gtt act ctc ttc cct cct agt tct gaa gag 350 Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu 70 75 80 ctt caa gct aac aag gct act ctt gtt tgc ttg atc agt gac ttt tat 398 Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr 85 90 95 cct ggt gct gtt act 413 Pro Gly Ala Val Thr 100 98 103 PRT Artificial Sequence Description of Artificial Sequence 2a2 JH2 Human lambda-chain gene with stuffers in place of CDRs 98 Ser Ala Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro 1 5

10 15 Gly Gln Ser Ile Thr Ile Ser Cys Thr Arg Ser Pro His Pro Gly Lys 20 25 30 Ala Pro Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser 35 40 45 Leu Thr Ile Ser Gly Leu Gln Gly Gly Gly Thr Lys Leu Thr Val Leu 50 55 60 Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser 65 70 75 80 Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp 85 90 95 Phe Tyr Pro Gly Ala Val Thr 100 99 10 DNA Artificial Sequence Description of Artificial Sequence Synthetic oligonucleotide 99 ctgtctgaac 10

Claims

1. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a heavy chain CDR1 selected from the group consisting of: (1) <1>.sub.1Y.sub.2<1>.sub.3M.sub.4<1>.sub.5, wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; (2) (S/T).sub.1(S/G/X).sub.2(S/G/X).sub.3Y.sub.4Y.sub.5W.sub.6(S/G/X).sub.7. wherein (S/T) is a 1:1 mixture of S and T residues, (S/G/X) is a mixture of 0.2025 S, 0.2025, G and 0.035 of each of amino acid residues A, D, E, F, H, I, K, L, M, N, P, Q, R, T, V, W, and Y; (3) V.sub.1S.sub.2G.sub.3G.sub.4S.sub.5I.sub.6S.sub.7<<1>.sub.8<1- >.sub.9<1>.sub.10Y.sub.11Y.sub.12W.sub.13<1>.sub.14, wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H,. I, K, L, M, N, P, Q, R, S, T, V, W, and Y; and (4) mixtures of vectors or genetic packages characterized by any of the above DNA sequences.

2. The focused library according to claim 1, wherein HC CDR1s (1), (2) and (3) are present in the library in the ratio 0.80:0.17:0.02.

3. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody facility, the vectors or genetic packages being characterized by variegated DNA sequences that encode a heavy chain CDR2 selected from the group consisting of: (1) <2>I<2><3>SGG<1>T<1>YADSVKG, wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; <2> is an equimolar mixture of each of amino acid residues Y, R, W, V, G, and S; and <3> is an equimolar mixture of each of amino acid residues P, S, and G or an equimolar mixture of P and S; (2) <1>I<4><1><1><G><5><1><1>- <1>YADSVKG, wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; <4> is an equimolar mixture of residues D, I, N, S, W, Y; and <5> is an equimolar mixture of residues S, G, D and N; (3) <1>I<4><1><1>G<5><1><1>YNPSLKG, wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and <4> and <5> are as defined above; (4) <1>I<8>S<1><1><1>GGYY<1>YAASVKG, wherein <1> is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; <8> is 0.27 R and 0.027 of each of ADEFGHIKLMNPQSTVWY; and (5) mixtures of vectors or genetic packages characterized by any of the above DNA sequences.

4. The focused library according to claim 3 wherein a mixture of HC CDR2s (1)/(2) (equimolar), (3) and (4) are present in the library in a ratio of 0.54:0.43:0.03.

5. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a heavy chain CDR3 selected from the group consisting of: (1) YYCA21111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R; (2) YYCA2111111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R; (3) YYCA211111111YFDAYTG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R; (4) YYCAR111S2S3111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of S and G; and 3 is an equimolar mixture of Y and W; (5) YYCA2111CSG11CY1YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R; (6) YYCA211S1TIFG11111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R; (7) YYCAR111YY2S3344111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; 2 is an equimolar mixture of D and S; and 3 is an equimolar mixture of S and G; (8) YYCAR1111YC2231CY111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P,. Q, R, S, T, V, W and Y; 2 is an equimolar mixture of S and G; and 3 is an equimolar mixture of T, D and G; and (9) mixtures of vectors or genetic packages characterized by any of the above DNA sequences.

6. The focused library according to claim 5, wherein 1 in one or all of HC CDR3s (1) through (8) is 0.095 of each of G and Y and 0.048 of each of A, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, and W.

7. The focused library according to claim 5 or 6, wherein HC CDR3s (1) through (8) are present in the library in the following proportions: (1) 0.10 (2) 0.14 (3) 0.25 (4) 0.13 (5) 0.13 (6) 0.11 (7) 0.04 and (8) 0.10

8. The focused library according to claim 5 or 6, wherein the HC CDR3s (1) through (8) are present in the library in the following proportions: (1) 0.02 (2) 0.14 (3) 0.25 (4) 0.14 (5) 0.14 (6) 0.12 (7) 0.08 and (8) 0.11

9. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encodes a kappa light chain CDR1 selected from the group consisting of: (1) RASQ<1>V<2><2><3>LA (2) RASQ<1>V<2><2><2><3>LA; wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <2> is 0.2 S and 0.044 of each of ADEFGHIKLMNPQRTVWY; and <3> is 0.2Y and 0.044 each of ADEFGHIKLMNPQRTVW and Y; and (3) mixtures of vectors or genetic packages characterized by any of the above DNA sequences.

10. The focused library of claim 9, wherein CDR1s (1) and (2) are present in the library in a ratio of 0.68:0.32.

11. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a kappa light chain CDR2 having the sequence: <1>AS<2>R<4><1>, wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <2> is 0.2 S and 0.044 of each of ADEFGHIKLMNPQRTVWY; and <4> is 0.2 A and) 0.044 each of DEFGHIKLMNPQRSTVWY.

12. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a kappa light chain CDR3 selected from the groups consisting of: (1) QQ<3><1><1><1>P<1>T, wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <3> is 0.2 Y and 0.044 each of ADEFGHIKLMNPQRTVW; (2) QQ33111P, wherein 1 and 3 are as defined in (1) above; (3) QQ3211PP1T, wherein 1 and 3 are as defined in (1) above and 2 is 0.2 S and 0.044 each of ADEFGHIKLMNPQRTVWY; and (4) mixtures of vectors or genetic packages characterized by any of the above DNA sequences.

13. The focused library according to claim 12, wherein CDR3s (1), (2) and (3) are present in the library in a ratio of 0.65:0.1:0.25.

14. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a lambda light chain CDR1 selected from the group consisting of: (1) TG<1>SS<2>VG<1><3><2><3>VS, wherein <1> is 0.27 T, 0.27 G and 0.027 each of ADEFHIKLMNPQRSVWY, <2> is 0.27 D, 0.27 N and 0.027 each of AEFGHIKLMPQRSTVWY, and <3> is 0.36 Y and 0.036 each of ADEFGHIKLMNPQRSTVW; (2) G<2><4>L<4><4><4><3><4><4&gt- ;, wherein <2> is as defined in (1) above and <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; and (3) mixtures of vectors or genetic packages characterized by any of the above DNA sequences.

15. The focused library according to claim 14, where CDR1s (1) and (2) are present in the library in a ratio of 0.67:0.33.

16. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a lambda light chain CDR2 has the sequence: <4><4><4><2>RPS, wherein <2> is 0.27 D, 0.27 N, and 0.027 each of AEFGHIKLMPQRSTVWY and <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVW.

17. A focused library of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of human antibody related peptides, polypeptides and proteins and collectively display, display and express, or comprise at least a portion of the diversity of the antibody family, the vectors or genetic packages being characterized by variegated DNA sequences that encode a lambda light chain CDR3 selected from the group consisting of: (1) <4><5><4><2><4>S<4><4><4>- <4>V, wherein <2> is 0.27 D, 0.27 N, and 0.027 each of AEFGHIKLMPQRSTVWY; <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVW; and <5> is 0.36 S and 0.0355 each of ADEFGHIKLMNPQRTVWY; (2) <5>SY<1><5>S<5><1><4>V, wherein <1> is an equimolar mixture of ADEFGHIKLMNPQRSTVWY; and <4> and <5> are as defined in (1) above; and (3) mixtures of vectors or genetic packages characterized by any of the above DNA sequences.

18. The focused library according to claim 17, wherein CDR3s (1) and (2) are present in the library in an equimolar mixture.

19. The focused library according to claim 1 or 2 further comprising variegated DNA sequences that encode a heavy chain CDR selected from the group consisting of: (1) one or more of the heavy chain CDR2s defined in claim 3 or 4; (2) one or more of the heavy chain CDR3s defined in claims 5, 6, 7, or 8; and (3) mixtures of vectors or genetic packages characterized by (1) and (2).

20. The focused library according to claim 3 further comprising variegated DNA sequences that encodes one or more heavy chain CDR3s selected from the group defined in claims 5, 6, 7 or 8.

21. The focused library according to claim 19 or 20, further comprising variegated DNA sequences that encodes a light chain CDR selected from the group consisting of (1) one or more the kappa light chain CDR1s defined in claim 9 or 10; (2) the kappa light chain CDR2 defined in claim 11; (3) one or more of the kappa light chain CDR3s defined in claim 12 or 13; (4) one or more of the kappa light chain CDR1s defined in claim 14 or 15; (5) the lambda light chain CDR2 defined in claim 16; (6) one or more of the lambda light chain CDR3s defined in claim 17 or 18; and (7) mixtures of vectors and genetic packages characterized by one or more of (1) through (6).

22. A population of variegated DNA sequences that encode a heavy chain CDR1 selected from the group consisting of: (1) <1>.sub.1Y.sub.2<1>.sub.3M.sub.4<1>.sub.5, wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; (2) (S/T).sub.1(S/G/X).sub.2 (S/G/X).sub.3Y.sub.4Y.sub.5W.sub.6(S/G/X).sub.7 wherein (S/T) is a 1:1 mixture of S and T residues, (S/G/X) is a mixture of 0.2025 S, 0.2025 G and 0.035 of each of amino acid residues A, D, E, F, H, I, K, L, M, N, P, Q, R, T, V, W, and Y; (3) V.sub.1S.sub.2G.sub.3G.sub.4S.sub.5I.sub.6S.sub.7<1>.sub.8<1>- .sub.9<1>.sub.10Y.sub.11Y.sub.12W.sub.13<1>.sub.14, wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M,. N, P, Q, R, S, T, V, W, and Y; and (4) mixtures of variegated DNA sequences characterized by any of the above DNA sequences.

23. The population of variegated DNA sequences according to claim 22, wherein HC CDR1s (1), (2) and (3) are present in the population in the ratio 0.80:0.17:0.02.

24. A population of variegated DNA sequences that encode a heavy chain CDR2 selected from the group consisting of: (1) <2>I<2><3>SGG<1>T<1>YADSVKG, wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; <2> is an equimolar mixture of each of amino acid residues Y, R, W, V, G, and S; and <3> is an equimolar mixture of each of amino acid residues P, S, and G or an equimolar mixture of P and S; (2) <1>I<4><1><1><G><5><1><1>- <1>YADSVKG, wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, and Y; <4> is an equimolar mixture of residues D, I, N, S, W, Y; and <5> is an equimolar mixture of residues S, G, D and N; (3) <1>I<4><1><1>G<5><1><1>YNPSLKG, wherein <1> is an equimolar mixture of each of amino acid residues A, D, E, F, G, H, I, K, L, M, N, P,. Q, R, S, T, V, W and Y; and <4>and <5> are as defined above; (4) <1>I<8>S<1><1><1>GGYY<1>YAASVKG, wherein <1> is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; <8> is 0.27 R and 0.027 of each of ADEFGHIKLMNPQSTVWY; and (5) mixtures of variegated DNA sequences characterized by any of the above DNA sequences.

25. The population of variegated DNA sequences according to claim 24, wherein a mixture of HC CDR2s (1)/(2) (equimolar), (3) and (4) are present in the population in a ratio of 0.54:0.43:0.03.

26. A population of variegated DNA sequences that encode a heavy chain CDR3 selected from the group consisting of: (1) YYCA21111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R; (2) YYCA2111111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R; (3) YYCA211111111YFDAYTG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R; (4) YYCAR111S2S3111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of S and G; and 3 is an equimolar mixture of Y and W; (5) YYCA2111CSG11CY1YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R; (6) YYCA211S1TIFG11111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; and 2 is an equimolar mixture of K and R; (7) YYCAR111YY2S3344111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; 2 is an equimolar mixture of D and S; and 3 is an equimolar mixture of S and G; (8) YYCAR1111YC2231CY111YFDYWG, wherein 1 is an equimolar mixture of each amino acid residues A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W and Y; 2 is an equimolar mixture of S and G; and 3 is an equimolar mixture of T, D and G; and (9) mixtures of variegated DNA sequences characterized by any of the above DNA sequences.

27. The population of variegated DNA according to claim 26, wherein 1 in one or all of HC CDR3s (1) through (8) is 0.095 of each of G and Y and 0.048 of each of A, D, E, F, H, I, K, L, M, N, P, Q, R, S, T, V, and W.

28. The population of variegated DNA sequences according to claim 26 or 27, wherein HC CDR3s (1) through (8) are present in the population in the following proportions: (1) 0.10 (2) 0.14 (3) 0.25 (4) 0.13 (5) 0.13 (6) 0.11 (7) 0.04 and (8) 0.10

29. The population of variegated DNA sequences according to claim 26 or 27, wherein the HC CDR3s (1) through (8) are present in the population in the following proportions: (1) 0.02 (2) 0.14 (3) 0.25 (4) 0.14 (5) 0.14 (6) 0.12 (7) 0.08 and (8) 0.11

30. A population of variegated DNA sequences that encode a kappa light chain CDR1 selected from the group consisting of: (1) RASQ<1>V<2><2><3>LA (2) RASQ<1>V<2><2><2><3>LA; wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <2> is 0.2 S and 0.044 of each of ADEFGHIKLMNPQRTVWY; and <3> is 0.2Y and 0.044 each of ADEFGHIKLMNPQRTVW and Y; and (3) mixtures of variegated DNA sequences characterized by any of the above DNA sequences.

31. The population of variegated DNA sequences of claim 30, wherein CDR1s (1) and (2) are present in the population in a ratio of 0.68:0.32.

32. A population of variegated DNA sequences that encode a kappa light chain CDR2 having the sequence: <1>AS<2>R<4><1>, wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <2> is 0.2 S and 0.044 of each of ADEFGHIKLMNPQRTVWY; and <4> is 0.2 A and) 0.044 each of DEFGHIKLMNPQRSTVWY.

33. A population of variegated DNA sequences that encode a kappa light chain CDR3 selected from the groups consisting of: (1) QQ<3><1><1><1>P<1>T, wherein <1> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; <3> is 0.2 Y and 0.044 each of ADEFGHIKLMNPQRTVW; (2) QQ33111P, wherein 1 and 3 are as defined in (1) above; (3) QQ3211PPlT, wherein 1 and 3 are as defined in (1) above and 2 is 0.2 S and 0.044 each of ADEFGHIKLMNPQRTVWY; and (4) mixtures of variegated DNA sequences characterized by any of the above DNA sequences.

34. The population of variegated DNA sequences according to claim 33, wherein CDR3s (1) , (2) and (3) are present in the population in a ratio of 0.65:0.1:0.25.

35. A population of variegated DNA sequences that encode a lambda light chain CDR1 selected from the group consisting of: (1) TG<1>SS<2>VG<1><3><2><3>VS, wherein <1> is 0.27 T, 0.2.7 G and 0.027 each of ADEFHIKLMNPQRSVWY, <2> is 0.27 D, 0.27 N and 0.027 each of AEFGHIKLMPQRSTVWY, and <3> is 0.36 Y and 0.036 each of ADEFGHIKLMNPQRSTVW; (2) G<2><4>L<4><4><4><3><4><4&gt- ;, wherein <2> is as defined in (1) above and <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVWY; and (3) mixtures of variegated DNA sequences characterized by any of the above DNA sequences.

36. The population of variegated DNA sequences according to claim 35, where CDR1s (1) and (2) are present in the population in a ratio of 0.67:0.33.

37. A population of variegated DNA sequences that encode a lambda light chain CDR2 has the sequence: <4><4><4><2>RPS, wherein <2> is 0.27 D, 0.27 N, and 0.027 each of AEFGHIKLMPQRSTVWY and <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVW.

38. A population of variegated DNA sequences that encode a lambda light chain CDR3 selected from the group consisting of: (1) <4><5><4><2><4>S<4><4><4>- <4>V, wherein <2> is 0.27 D, 0.27 N, and 0.027 each of AEFGHIKLMPQRSTVWY; <4> is an equimolar mixture of amino acid residues ADEFGHIKLMNPQRSTVW; and <5> is 0.36 S and 0.0355 each of ADEFGHIKLMNPQRTVWY; (2) <5>SY<1><5>S<5><1><4>V, wherein <1> is an equimolar mixture of ADEFGHIKLMNPQRSTVWY; and <4> and <5> are as defined in (1) above; and (3) mixtures of variegated. DNA sequence characterized by any of the above DNA sequences.

39. The population of variegated DNA sequences according to claim 38, wherein CDR3s (1) and (2) are present in the population in an equimolar mixture.

40. The population of variegated DNA sequences according to claim 22 or 23 further comprising variegated DNA sequences that encode a heavy chain CDR selected from the group consisting of: (1) one or more of the heavy chain CDR2s defined in claim 24 or 25; (2) one or more of the heavy chain CDR3s defined in claims 26, 27, 28 or 29; and (3) mixtures of variegated DNA sequence characterized by (1) and (2).

41. The population of variegated DNA sequences according to claim 24 further comprising variegated DNA sequences that encodes one or more heavy chain CDR3s selected from the group defined in claims 26, 27, 28 or 29.

42. The population of variegated DNA sequences according to claim 40 or 41 further comprising variegated DNA sequences that encodes a light chain CDR selected from the group consisting of (1) one or more the kappa light chain CDR1s defined in claim 30 or 31; (2) the kappa light chain CDR2 defined in claim 32; (3) one or more of the kappa light chain CDR3s defined in claim 33 or 34; (4) one or more of the kappa light chain CDR1s defined in claim 35 or 36; (5) the lambda light chain CDR2 defined in claim 37; (6) one or more of the lambda light chain CDR3s defined in claim 38 or 39; and (7) mixtures of variegated DNA sequences characterized by one or more of (1) through (6).

43. A population of vectors comprising the variegated DNA sequences of any one of claims 22-42.